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Obesity constitutes one of the most important metabolic diseases being associated to
insulin resistance development and increased cardiovascular risk. Association between
obesity and cancer has also been well established for several tumor types, such as breast
cancer in post-menopausal women, colorectal, and prostate cancer. Cancer is the first
death cause in developed countries and the second one in developing countries, with high
incidence rates around the world. Furthermore, it has been estimated that 15–20% of all
cancer deaths may be attributable to obesity. Tumor growth is regulated by interactions
between tumor cells and their tissue microenvironment. In this sense, obesity may lead to
cancer development through dysfunctional adipose tissue and altered signaling pathways.
In this review, three main pathways relating obesity and cancer development are exam-
ined: (i) inflammatory changes leading to macrophage polarization and altered adipokine
profile; (ii) insulin resistance development; and (iii) adipose tissue hypoxia. Since obesity
and cancer present a high prevalence, the association between these conditions is of great
public health significance and studies showing mechanisms by which obesity lead to can-
cer development and progression are needed to improve prevention and management of
these diseases.
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INTRODUCTION
Obesity has reached epidemic proportions constituting one of the
most important diseases of this century (1). Despite body mass
index (BMI) being used for a long time as the best way to diagnose
and define obesity, recent studies have proposed that BMI mis-
classified subjects with increased cardiovascular risk factors (2).
This finding highlights that BMI underestimates the real preva-
lence of overweight and obesity, since it only considers weight and
height of the patients and not total body fat, which really defines
the obesity-associated comorbidity risk. In this regard, other indi-
cators to determine the prevalence of obesity have been proposed
with body fat percentage being one of the most useful due to its
superior ability to stratify patients according to their metabolic
and cardiovascular risks (3, 4).
Health care expenditure in severe obesity (BMI≥ 40 or
≥35 kg/m2 with manifest serious comorbidities) is greater than
the investment in any other medical condition (5). This is not
only due to direct consequences of obesity, but also due to their
associated comorbidities. There are numerous evidences of the
relationship between obesity and type 2 diabetes mellitus (T2D)
(6), non-alcoholic fatty liver disease (NAFLD) (7, 8) and other
chronic liver diseases such as cirrhosis (9), obstructive sleep
apnea (OSA) syndrome (10), other respiratory alterations (11)
as well as cardiovascular diseases (CVD) including cerebrovascu-
lar disorders and hypertension (12–14). Furthermore, evidence
about the relationship between obesity and several types of can-
cer is increasing (15–19). These tumors include colon, breast,
endometrium, prostate, thyroid, renal, esophagus, gastric cardia,
pancreas,gallbladder,and liver cancer as well as non-Hodgkin lym-
phoma and multiple myeloma (15, 20–23). Nowadays, cancer is
probably one of the most important diseases due to its high preva-
lence and mortality rates (24). According to the National Cancer
Institute, a total of 1,660,290 new cancer cases and 580,350 cancer
deaths would take place in the United States in 2013 (25). Increas-
ing trends in incidence of the most common cancers in Europe are
also of concern, in particular for colorectal cancer, where incidence
is high and still continues to increase (26, 27). A large proportion
of the studied cancers are potentially avoidable (28), and several
programs to prevent or detect early stages of cancer have been pro-
posed, such as gynecologic or colon cancer population screenings
(29–31). Importantly, it has been estimated that 15–20% of all
cancer deaths in the United States can be attributed to overweight
and obesity (32–34). Obesity and cancer affect millions of people
with important consequences; thereby a comprehensive approxi-
mation to the mechanisms underlying their relationship is needed
to ensure better prevention and treatment strategies.
Higher BMIs have been associated with increased risk of dis-
ease while at the same time they have been related with a lower
mortality and a better outcome in several chronic diseases (35).
This paradoxical finding is shared over a variety of cardiovascular,
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pulmonary, and renal diseases and is known as the obesity para-
dox (36). There is increasing evidence that patients, especially
elderly, with elevated BMI and several chronic diseases exhibit
lower all-cause mortality compared with normal-weight patients
(37). However, it should be highlighted that the BMI is an anthro-
pometric marker that does not consider total body fat mass and
distribution, nutritional status, or other factors influencing health
risks (2, 3, 38).
RELATIONSHIP BETWEEN OBESITY AND CANCER
Large prospective studies show a significant association between
excess adiposity and several cancers. There is sufficient evidence
relating obesity and tumor development of the colon, breast
(post-menopausal women), and prostate among others (18).
Breast cancer is the most frequently diagnosed cancer globally
and the second cause of cancer death in women. It has been esti-
mated that breast cancer constituted 30% of all new cancer cases
in women in 2013 (25). Overweight and obesity are important risk
factors for breast cancer development and, in contrast to other risk
factors, such as menstruation age, familiar antecedents or aging,
both overweight and obesity are preventable. It has been shown
that post-menopausal obese women present a threefold increase in
the risk of breast cancer compared to the non-obese control group
(39). Moreover, other studies have revealed that higher BMI is
associated with worse response to neoadjuvant chemotherapy and
worse overall survival (40). Other anthropometric measurements,
such as the waist-to-hip ratio, also correlate with breast cancer
death risk (41). Worse prognosis or survival rates in obese women
with breast cancer have been established in different studies (42–
44), showing that obesity is an important risk factor for breast
cancer and, therefore, therapeutic measures must be adopted to
reduce obesity incidence. It is important to take into account
that hormone replacement therapy (45, 46) and mammographic
density (47) could be additional confounders in these association
studies. The obesity-associated increased risk of post-menopausal
breast cancer might be explained by higher rates of peripheral con-
version of androgenic precursors to estradiol due to an increased
aromatase enzyme activity in adipose tissue (48).
Globally, colorectal cancer remains the third most commonly
diagnosed in males and the second in females with a cumulative
life risk of developing colorectal cancer of 5% in the general popu-
lation (49). Although both, the incidence and mortality have been
slowly but steadily decreasing, colorectal cancer is the third lead-
ing cause of cancer-related deaths (25). The relationship between
obesity and colon cancer is well established (50–53). In this regard,
it has been estimated that about 30% of all colon cancer cases
could be attributable to a BMI higher than 22.5 kg/m2 (54). BMI
appears to be consistently associated with an increased risk of col-
orectal cancer in men, but only a weak association in women has
been described (48). This gender difference might be explained
by sex differences in prevalence and age of the onset of meta-
bolic syndrome, or by a protective effect of estrogens, inducing
apoptosis and inhibition of cell proliferation (55, 56). However,
a recent meta-analysis showed that BMI is positively related with
colon cancer in both men and women, and no gender differences
were found (57). In this sense, a positive association between
BMI and prevalence of colonic adenoma and advanced polyps
has been demonstrated in pre-menopausal women according to
hormonal status (58). Obesity has also been associated with worse
cancer outcomes, such as recurrence of the primary cancer or
increased mortality. Several factors, including reduced sensitiv-
ity to antiangiogenic–therapeutic regimens, might explain these
differences. The underlying mechanisms linking obesity to col-
orectal cancer are not completely elucidated, but inflammation,
insulin resistance, and a dysregulated adipokine profile are pro-
posed as important factors. Other biological factors such as the
gut microbiota (59) or bile acid concentrations are emerging as
novel influential factors in obesity-associated tumors (55).
Prostate cancer is the second diagnosed cancer and the sixth
cause of cancer-related mortality among men worldwide (60).
Because obesity and prostate cancer affect substantial proportions
of the male population, the association between these conditions is
of great public health significance. In the last decade, multiple epi-
demiologic studies have suggested that obesity is associated with
an increased risk of death from numerous cancer types including
prostate cancer (32, 48). Three meta-analyses reported a posi-
tive association between obesity and prostate cancer incidence
and, although modest, the relative risks were consistent (48, 61,
62). Obesity has also been associated with worse prognostic and
malignant transformation of epithelial cells (63, 64). However,
there are contradictory studies about the link between obesity and
prostate cancer (65) reporting no association (64, 66), and even a
protective effect of obesity (67–71). Proposed obesity-associated
alterations related to prostate tumor development include lower
levels of sex hormone-binding globulin that increase the fraction
of biologically available testosterone (15).
Lung cancer is the main cause of cancer-related death in both
genders, with an estimated incidence of more than 200,000 cases in
2013 in the United States (25). To date, the relationship between
obesity and the incidence of lung cancer remains unclear (72).
Controversy still focuses on the effect of smoking in studies inves-
tigating the relationship between BMI and lung cancer (73). In
case–control studies, odds ratios for lung cancer by levels of BMI
showed an increasing linear trend with a lower threshold BMI for
current smokers and ex-smokers of both sexes (74, 75). Moreover,
an inverse association between BMI and lung cancer has been
shown in other studies after adjusting for smoking or waist cir-
cumference (76–78). In this sense, a recent meta-analysis indicates
that overweight and obesity are protective factors against lung can-
cer, especially in current and former smokers (72). Recently, the
involvement of adipokines in lung cancer is under study due to
their emerging carcinogenic and immunomodulatory properties,
making them potential mediators of the complex and still unclear
multistep carcinogenetic process (79).
Association with obesity has also been proposed for other
cancer types, as thyroid, kidney, esophagus, gastric cardia, pan-
creas, gallbladder, or liver cancer, but further studies are needed to
confirm the obesity-attributable risk of tumor development.
DYSFUNCTIONAL ADIPOSE TISSUE IN OBESITY AND TUMOR
DEVELOPMENT
Obesity is described as an excess of adiposity due to a prolonged
status of positive energy balance, which leads not only to changes
in adipose tissue distribution but also to metabolic alterations as
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well as altered cytokine and lipid secretion profiles. Energy balance
and fuel homeostasis require a tight equilibrium between energy
intake (chemical energy from diet-derived macronutrients) and
energy expenditure [basal metabolic rate plus mechanical energy
by muscle contractions due to physical activity (PA)] that are reg-
ulated by both central and peripheral mechanisms. In this sense,
substantial changes have occurred in the patterns of foods con-
sumed with special concern about excess of sugar intake in the
diet in many industrialized countries mainly as sugar-sweetened
drinks (80, 81).
There are two main types of adipose tissue, white and brown,
with different origins and functions (82). The major role of white
adipose tissue (WAT) is related to maintaining energy homeosta-
sis by storing triglycerides and releasing fatty acids for energy
synthesis. It has been well established that WAT also controls a
wide variety of functions including immune and inflammatory
regulation, glucose and lipid homeostasis, food intake control, or
metabolism by secreting a great number of adipokines (83, 84).
WAT is a heterogeneous tissue, consisting of a peripheral subcu-
taneous component (SAT) and a central intra-abdominal com-
ponent [visceral adipose tissue (VAT)] (85). Abdominal obesity
seems to be of greater pathophysiological concern than subcuta-
neous fat with an increase in VAT being strongly correlated with
the metabolic syndrome and tumor development (86–88). Brown
adipose tissue (BAT) was initially described to play a physiological
role in animals and infants. In human neonates, BAT is located
in specific depots, the interscapular and axillary region, and to a
lesser extent, near to the thymus and in the dorsal midline region
of the thorax and abdomen (89). However, recent studies using
positron emission tomography imaging techniques documented
the presence of functional BAT in adult humans (90–92). BAT is
specialized in thermogenesis, the production of heat mainly medi-
ated by the uncoupling protein-1 (UCP-1), which produces heat by
uncoupling mitochondrial respiration for ATP synthesis (93, 94).
Cancer has been associated with cachexia, a complex syndrome
that involves profound metabolic imbalances (95). The colorec-
tal tumor-induced cachexia on BAT in mice has been described,
finding smaller brown adipocytes with profound delipidation in
cachectic tumor-bearing mice (96). Recently, the existence of a
third kind of adipose tissue has been proposed, the “beige” or
“brite” (brown-like adipocytes) adipose tissue (97). Beige adi-
pose tissue is also a thermogenic adipose tissue influenced by
cold-induced signals via the sympathetic nervous system.
Adipose tissue from obese subjects experiments a wide range
of modifications due to its expansion and the excessive amount of
lipids stored. The limitation in adipose tissue expandability leads
to fat accumulation in other parts of the body with lipotoxic con-
sequences (98). Expanded fat depots in obesity are less efficient
in storing dietary fatty acids, so that obese subjects exhibit an
increase in plasma free fatty acids (FFA) and ectopic fat depots. The
higher levels of FFA are susceptible to be substrates for oxidative
processes and also may function as mediators of insulin resistance
in muscle (99) or liver (100, 101). An analysis of cancer-induced
modifications in the lipid profile reveals important clues linking
obesity and cancer. Changes in lipid metabolism may promote
cancer development by an FFA increase, due to its function as
oncogenic signals (18). Reportedly, increased fatty acid synthase
(FASN) activity has been shown in breast cancer cell lines (102),
ovarian tumors (103), or cancer precursor lesions in different
locations (colon, stomach, esophagus, and oral cavity) (104). The
inhibition of the FASN activity reduces the cancer cells’ prolif-
erative capacity, suggesting that FFA act as an energy source for
cancer cells. In addition, some studies show a relationship between
mutations in the FASN enzyme and cancer incidence (105). Fur-
thermore, FASN has been proposed as an important biomarker of
overnutrition-induced insulin resistance (106). Elevated FFA lev-
els derived either from the cancer cell or exogenous fat sources may
promote a more aggressive tumorigenic phenotype with the impli-
cation of monoacylglycerol lipase (107). Finally, different studies
suggest that cancer cells may use lipids directly from adipocytes as
energy source, promoting tumor growth (108).
PATHOPHYSIOLOGICAL MECHANISMS RELATING VISCERAL
ADIPOSE TISSUE EXCESS AND CANCER
Several mechanisms whereby obesity can favor cancer develop-
ment and progression have been proposed, including the obesity-
associated low-grade inflammation, endocrine alterations, insulin
resistance, and hypoxia–angiogenesis processes.
ADIPOSE TISSUE INFLAMMATION, A MICROENVIRONMENT FAVORING
TUMORIGENESIS
Obesity is characterized by a chronic state of low-grade inflam-
mation (109). Adipose tissue is composed of mature adipocytes
and stromal cells, which include preadipocytes, fibroblasts as well
as vascular and immune cells. The interaction between immune
cells and adipocytes leads to inflammation and subsequent adi-
pose tissue dysfunction. Chronic inflammation is characterized by
a sustained response to diverse stress signals, which leads to adi-
pose tissue remodeling (110–112). This process includes adipocyte
hypertrophy, immune cell infiltration, angiogenesis, and fibrosis
during the progression of inflammation (113–116) accompanied
with changes in the adipokine production profile (117). The link
between chronic inflammation and cancer development was first
noticed over 100 years ago by Virchow, when he observed an abun-
dance of leukocytes in neoplastic tissue (118). Since then, the role
of chronic inflammation as a precursor of cancer development has
been observed in multiple cancer types (119). In animal models of
human cancers, inflammation has been shown to influence tumor
promotion and progression (120–122). Like adipose tissue, tumor
microenvironment is composed of multiple cell types includ-
ing epithelial cells, fibroblasts, mast cells, and cells of the innate
and adaptive immune system that favors a pro-inflammatory and
pro-tumorigenic environment (123–127).
Macrophages, obesity, and cancer
Growing evidence reveals that adipose tissue from obese sub-
jects is markedly infiltrated by macrophages that participate in
inflammatory pathways with important roles in obesity-associated
comorbidities (128). Adipose tissue macrophages (ATM) enhance
the levels of inflammatory markers dysregulated in cancer, sug-
gesting that macrophages from peritumoral adipose tissue are
locally involved in promoting carcinogenesis (129–131). The pres-
ence of tumor-associated macrophages (TAM) also contributes
to the pro-inflammatory tumor environment. The recruitment
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of TAM to the tumor microenvironment is largely dependent
on the monocyte chemoattractant protein-1 (MCP-1). In this
regard, levels of MCP-1 in tumor tissue have been highly correlated
with the accumulation of TAM in ovarian, breast, and pancreatic
cancer (123, 132).
Local environment factors are able to determine polarization of
macrophages through two general states: M1 (pro-inflammatory)
and M2 (anti-inflammatory) macrophages (Figure 1). Activation
of M1 macrophages is mediated mainly through the nuclear fac-
tor κ-light-chain-enhancer of activated B cells (NF-κB) and Jun
N-terminal kinase (JNK)/activator protein-1 (AP-1) system. M1
macrophage-derived tumor necrosis factor (TNF)-α and inter-
leukin (IL)-18, 12, and 23 have been identified as important
mediators in several chronic inflammatory diseases including
obesity and cancer (133–136). Excess of M1 macrophage polar-
ization is related to insulin resistance in obese subjects (137)
with M1 macrophages being also differentiated in the tumor
initiation stages. Obesity could lead to tumor initiation by the
denominated extrinsic pathway, in which tumorigenesis is attrib-
utable to a chronic inflammatory condition through the NF-κB
pathway (138). NF-κB activation in tumor cells promotes car-
cinogenesis by increasing their aggressive potential by trigger-
ing autocrine growth factor cascades and by inhibiting prolif-
eration control mechanisms, including apoptotic signals (139).
NF-κB involvement in tumorigenesis has been shown in vari-
ous tumor models (140). M1 macrophages also contribute to
tumor development by TNF-α and IL-6 signaling, enhancing
carcinogenesis by increasing cell proliferation and neoangio-
genic cell properties (141, 142). In addition, TNF-α produc-
tion by macrophages activates the Wnt/β-catenin pathway, which
is also associated with tumor development by a non-resulting
anti-inflammatory response (143, 144). M2 macrophage acti-
vation is mainly mediated by the IL-4-induced activation of
Janus kinase (JAK)/signal transducer and activator of transcrip-
tion (STAT) transduction signaling. It has been shown that IL-10
secreted by M2 macrophages improves insulin signaling, with a
protective role in obesity-induced insulin resistance (145). More-
over, several factors are involved in M2 activation, such as per-
oxisome proliferator-activated receptor (PPAR)-γ, Krüppel-like
factor 4, AMP-activated protein kinase (AMPK), or sirtuin-1
(SIRT1) (146).
In adipose tissue from obese subjects, there is a phenotype
switch from M2 to M1 macrophages leading to an increase in
general inflammatory markers (147). Moreover, during tumor
progression, an M2 to M1 transition of ATM has been shown.
However, in later tumor stages, a trophic and immunomodula-
tory M2-like adipose tissue macrophage phenotype is recruited
to the tumor environment. It has been proposed that M2 dif-
ferentiation could act as a compensatory mechanism, trying to
re-establish a homeostatic environment in a pathological condi-
tion (144). Mechanisms involved in this M1–M2 switch are not
well understood, but molecular pathways related to cyclooxyge-
nase (COX)-2, toll-like receptor (TLR), or Notch signaling have
been proposed to play an important role (148–150). Macrophage
switch from M1 to M2 in tumor setting occurs via many different
receptors, signaling pathways, and transcription factors as a result
of the coexistence of pro- and anti-inflammatory signals present
during tumor progression in the tumor environment.
Dysregulated adipokine profile in obesity and cancer
The progression of tumors toward malignancy requires the inter-
action of various cytokines, growth factors, and transcription
factors. Adipose tissue acts as an important endocrine organ via
the synthesis of several adipokines, which regulate insulin sensitiv-
ity, lipolysis, control of energy intake, or inflammatory processes
(151–153). Obesity affects the secretory profile of adipokines lead-
ing to alteration in multiple physiological processes (154–164).
Adipokines are linked to tumor development and progression due
to their plentiful actions on different cell types, mainly by exert-
ing their effects through inflammatory pathways. Adiponectin
and leptin are two of the most important adipocyte-specific
adipokines.
FIGURE 1 | Macrophages are representative of the innate immune
system and represent a large proportion of the stromovascular cell
fraction in adipose tissue. The phenotype of macrophages depends on
the subset of monocytes upon arrival at target tissues being probably
determined by the local microenvironment. Based on their cytokine
profile secretion and cell surface markers, macrophages are classified
into two main types: the “classical” macrophages named M1 in contrast
to the “alternatively activated” M2. M1 macrophages are the first line of
defense against intracellular pathogens and are classically stimulated by
interferon (IFN)-γ or by lipopolysaccharide (LPS). M1 induce the secretion
of inflammatory cytokines [interleukin (IL)-1, IL-6, tumor necrosis factor
(TNF)-α, or monocyte chemoattractant protein (MCP)-1]. Alternative
activation, resulting from induction by the Th2 cytokines interleukin IL-4
and IL-13, is associated with tissue repair and humoral immunity
producing immunosuppressive factors, including IL-10, IL-1Ra, and
arginase. Obesity and initial tumor stages induce a phenotypic switch
from an anti-inflammatory M2-polarized state to a pro-inflammatory M1
state.
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Adiponectin. Adiponectin, also known as Acrp30, ADIPOQ,
apM1, or GBP28, is a 30-kDa protein mainly secreted by adipocytes
(165). Adiponectin presents a carboxy-terminal globular domain
and an amino-terminal collagen domain that forms characteris-
tic multimers (166). Adiponectin exists as full-length adiponectin
or as a globular fragment. Globular adiponectin is generated
by proteolytic cleavage of full-length adiponectin, but it circu-
lates in very small amounts in the bloodstream (167). Globular
adiponectin exists as a trimer, whereas full-length adiponectin can
be found as a low-molecular weight (trimer), middle-molecular
weight (hexamers), and high-molecular weight (12–18mers) with
different biological functions (168, 169). Both globular and full-
length adiponectin promote an increased fatty acid oxidation
and glucose uptake in the liver and skeletal muscle as well as
a decreased hepatic gluconeogenesis. These biological effects are
mediated by two transmembrane adiponectin receptors, AdipoR1
and AdipoR2, which are expressed in many tissues and activate the
downstream targets AMPK, PPAR-α, and p38 MAPK (167).
Several studies suggest that hypoadiponectinemia or reduced
concentrations of adiponectin and PPAR-α in obesity may be one
of the mechanisms linking obesity and cancer development as
well as progression. Importantly, adiponectin levels are decreased
in obesity-associated insulin resistance (170) and cancer (171). A
negative correlation between adiponectin levels and the risk of
developing colorectal (52, 172, 173), endometrium (174), breast
(175), prostate (176), or pancreas cancer (177) has been shown.
In animal models, a protective role for adiponectin by suppressing
colorectal cancer development has been suggested (178). Adipoq-
knockout mice showed a significant higher polyp formation com-
pared with wild-type mice under a high-fat diet. Furthermore,
it was also demonstrated that Adipor1, but not Adipor2-deficient
mice show an increase in colonic epithelial cell proliferation, sug-
gesting that adiponectin suppresses this biological process under
a high-fat diet (178). Reduced adiponectin levels in the obese state
lead to the development of insulin resistance and compensatory
chronic hyperinsulinemia. Increased insulin levels lead to reduced
liver synthesis and secretion of insulin-like growth factor-binding
protein (IGFBP)-1 and -2, resulting in increased levels of bioavail-
able insulin-like growth factor (IGF)-1. Insulin and IGF-1 promote
cellular proliferation and inhibit apoptosis in many tissue types,
leading to carcinogenesis (15, 171). Low adiponectin levels are
potentially associated with carcinogenesis, indirectly through its
effects on TNF-α and tumor cell proliferation and directly by its
effects on the regulation of hematopoiesis and system, selective
binding to several mitogenic growth factors, and inhibition of
NF-κB (171, 179). The adiponectin protective effects in tumors
also include the inhibition of leptin proliferative signaling and
inducing cell apoptosis (180).
Leptin. Leptin, the OB gene product, acts as a key mediator in
body weight regulation (181–184). In adipose tissue, the secre-
tion levels of leptin are strictly controlled and maintain a balance
to ensure adequate regulation of food intake and energy expen-
diture under physiological conditions. Contrary to adiponectin,
leptin levels are increased in obese individuals (185). Reportedly,
treatment with leptin promotes cell growth, inhibits apoptosis,
and modulates migration of cancer cells (186). In this regard, an
overexpression of leptin receptors in various cancers like breast
(187) or colon (188) has been also shown. Tumor cells from pap-
illary thyroid cancer also show increased expression levels of the
leptin receptor being associated with a more aggressive pheno-
type (189). Mature adipocytes secrete both adiponectin and leptin
with preadipocytes showing a primarily secretion of high lep-
tin levels (190). An increase of the preadipocyte pool in obese
subjects is related to an increase in leptin levels, with proan-
giogenic and promitogenic properties (191). At the same time,
high leptin levels attract more inflammatory cells and promote
monocyte to macrophage differentiation, maintaining the obesity-
associated state of chronic inflammation. In summary, leptin has
an important role in the development of a large variety of malig-
nancies, predominantly acting through the JAK/STAT pathway,
which modulates phosphatidylinositol 3-kinase (PI3K)/Akt and
extracellular signal-regulated kinase (ERK) 1/2 signaling path-
ways increasing the expression of anti-apoptotic proteins (XIAP),
inflammatory markers (TNF-α, IL-6), angiogenic factors [vascular
endothelial growth factor (VEGF)],and also the hypoxia-inducible
factor-1α (HIF-1α). These processes promote cancer cell survival,
proliferation, and migration.
Tumor necrosis factor-α. TNF-α is a pro-inflammatory cytokine
secreted by adipocytes with increased secretion levels in obese sub-
jects (192). TNF-α was first identified as a macrophage-derived
factor that induces the necrosis of tumor cells, but when its
antitumoral activity was tested on cancer patients, a paradoxical
tumor-promoting role became apparent (193–195). At present,
the pro-inflammatory role of TNF-α has been linked to all steps
involved in tumorigenesis, including cellular transformation, sur-
vival, proliferation, invasion, angiogenesis, and metastasis (195,
196). Animal models have shown a positive relationship between
TNF-α and tumor development and progression in liver (197)
and colorectal cancer (195) with elevated circulating concentra-
tions in different tumoral types (198, 199). In addition, TNF-α is
not only produced by a wide variety of tumor cells (200) but also
by adipocytes. Levels of TNF-α are increased in obesity, indicating
a role for this cytokine in the obesity-associated inflammation and
particularly in insulin resistance and diabetes.
Interleukin-6. Interleukin-6 is another major pro-inflammatory
cytokine secreted by adipose tissue, which shows increased lev-
els in obese subjects. It has been implicated in inflammation-
associated carcinogenesis (201, 202). IL-6 modulates the expres-
sion of genes involved in proliferation, survival, and angiogenesis
via the JAK/STAT signaling pathway (203). A relationship between
IL-6 and carcinogenesis has been shown for renal cell carcinoma
(204), gastric cancer (205), or colorectal cancer, among others
(200, 206). Moreover, elevated levels of IL-6 in cancer patients
correlate with disease aggressiveness and poor prognosis (207,
208). Other studies have revealed the role of IL-6 as an anti-
inflammatory cytokine acting via the classic signaling through
the activation of the IL-6 receptor on the cellular membrane of
specific cell types such as macrophages, neutrophils, some T-cells,
and hepatocytes (209, 210).
C-reactive protein. C-reactive protein (CRP) is an acute-phase
reactant protein induced as a response to inflammatory conditions
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and different cytokines including IL-6. Elevated levels of CRP
in adipose tissue and serum of obese subjects have been shown
(211) as well as in patients with a variety of malignancies (212).
Prospective studies have shown a higher risk of developing can-
cer in those with elevated serum CRP (213, 214). Elevated CRP
is a significant predictor of lower survival rates in patients with
several cancers, including esophageal, colorectal, hepatocellular,
pancreatic, urinary bladder, renal, ovarian, and cervical cancer,
after surgical resection. CRP can serve as an additional prognostic
predictor for survival and post-treatment monitoring in cancer
patients (215).
Resistin. Resistin, also known as Fizz3, is a 12-kDa cysteine-rich
protein that plays a role in the development of insulin resistance
and obesity in rodents (216). While adipose tissue constitutes
the main source of resistin in mice, this molecule is secreted
mainly by monocytes and macrophages in humans (217). Human
resistin is implicated in the pathogenesis of atherosclerosis by pro-
moting smooth muscle cell proliferation and migration, ICAM-1
and VCAM-1 expression, as well as via regulating patterns of
adhesion and inflammation in atherosclerotic plaques (218, 219).
Several colorectal cancer studies have shown a positive corre-
lation between resistin and tumor size based on T-staging and
tumor grading (172, 220). Resistin has also been postulated as
a target molecule, which associates with clinicopathological fea-
tures and prognosis of pancreatic ductal adenocarcinoma (221).
Resistin has been postulated as a pro-inflammatory adipokine
(222), exhibiting significantly higher serum levels in patients
affected by breast cancer in comparison to controls. Additionally,
resistin has been proposed as a regulator of the human chorio-
carcinoma cell invasive behavior and endothelial cell angiogenic
processes (223).
Monocyte chemoattractant protein-1. MCP-1 is a chemokine
implicated in the infiltration of macrophages in adipose tissue.
Higher levels of MCP-1 can be found in obese subjects compared
with lean subjects (224). The presence of infiltrating macrophages
as a consequence of increased MCP-1 levels has been shown to
correlate with cancer metastasis and poor prognosis in a variety
of human carcinomas (172, 225). MCP-1 overexpression has been
reported in both ovarian cancer (226, 227) and colorectal cancer
(228).
Visfatin. Visfatin also known as pre-B cell colony enhancing fac-
tor (PBEF) or nicotinamide phosphoribosyltransferase (NAMPT)
is a 52-kDa protein with apparently insulin-mimetic actions (229)
and increased plasma concentrations in patients with obesity and
T2D (230). Since several authors could not replicate the insulin-
mimetic activities of visfatin as well as its ability to bind the
insulin receptor, Fukuhara and colleagues were forced to retract
some of their original findings (231). However, visfatin stimulates
glucose-induced insulin secretion in β-pancreatic cells (232, 233).
Visfatin has been further identified in inflammatory cells with its
levels being reportedly increased in various inflammatory con-
ditions (229). Visfatin has been related with carcinogenesis and
tumor progression, as well as with chemotherapy response (234)
in colorectal (235, 236) and breast cancer (237).
Osteopontin. Osteopontin (OPN), also known as secreted
phosphoprotein-1 (SPP1) and bone sialoprotein-1, among oth-
ers, is a phosphoprotein expressed by a wide variety of cell types,
including adipocytes (238). The expression levels of OPN are
increased in obesity (160, 239) as well as in other pathophysio-
logical processes including neoplastic transformation, progression
of metastases, and promotion of cell survival (240). OPN is also
expressed in many cancers, with elevated circulating levels and tis-
sular tumor expression being associated with poor prognosis in
gastric and liver cancers (241, 242).
Chitinase-3-like protein-1. Chitinase-3-like protein-1 (CHI3L1),
also known as YKL-40 or human cartilage glucoprotein-39, is a
member of mammalian chitinase-like proteins with increased gene
expression levels in obesity and T2D (155, 243). Recently, YKL-40
has been proposed as a new inflammatory marker related to insulin
resistance (244). YKL-40 is also increased in several types of solid
tumors contributing not only to the development of an inflam-
matory state but also to cell proliferation, inhibition of apoptosis,
stimulation of angiogenesis, and regulation of extracellular tissue
remodeling (245). Increased YKL-40 expression has been detected
in glioblastoma multiforme (246), papillary thyroid carcinoma
(247), extracellular myxoid chondrosarcoma (248), colon cancer
(131), and diverse cancer cell lines, being suggested as a useful
cancer prognostic biomarker (249).
Consequences of oxidative stress
Reactive oxygen species (ROS) comprise hydrogen peroxide
(H2O2), superoxide anion (
O2), and hydroxyl radical (HO)
and induce DNA mutations contributing to cancer development
and progression. Potential sources for ROS production in mito-
chondria include xanthine oxidase, cytochrome P450 oxidases,
uncoupled nitric oxide synthases, and NADPH oxidases (250).
Reactive oxygen species exert a wide range of effects in cancer
cells depending on their concentrations. In general, low levels of
ROS are mitogenic and promote cell proliferation and survival,
while intermediate levels cause transient or permanent cell cycle
arrest and induce cell differentiation (251). At high levels, ROS can
easily react with membrane lipids (causing membrane permeabil-
ity alteration), DNA (inducing damage and genomic instability),
and proteins (promoting oxidative modifications that result in less
active enzymes or proteins more susceptible to proteolytic degra-
dation). These facts suggest a possible protective effect of high
local ROS levels in cancer progression (252). However, although
ROS production does not irreversibly alter cell viability, they can
act as a primary messenger, modulating several intracellular sig-
naling cascades leading to cancer progression. Indeed, it has been
demonstrated that ROS activate the MAPK, PI3K/Akt, phospho-
lipase C-γ1 (PLCγ1), protein kinase C, NF-κB, and JAK/STAT
pathways (253). The increase of fat mass in obesity has been cor-
related with the increase of markers of systemic oxidative stress
in both human and mice (254, 255). In this regard, an increase
in the NADPH oxidase subunits in obesity has been described
(254), suggesting that adipose tissue may constitute a source of
ROS, releasing them into the peripheral blood, and affecting the
function of remote organs (256). Adipose tissue from lean subjects
expresses antioxidant enzymes (catalase, superoxide dismutase-1,
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and glutathione peroxidase) for managing ROS production, with
the expression of these antioxidant enzymes downregulated in
adipose tissue from obese individuals (254, 255, 257, 258).
Therapeutic approaches to cancer involving ROS metabolism
have been proposed in recent years. Experimental results have
proposed that the ROS increase is involved in apoptosis induction
by chemotherapeutic anticancer agents (259). Cancer cells with
increased oxidative stress are likely to be more vulnerable to dam-
age by further ROS insults induced by exogenous agents (260).
Therefore, manipulating ROS levels by redox modulation consti-
tutes a way to selectively induce cancer cell death without causing
significant toxicity to normal cells (261).
HORMONAL LINKS IN OBESITY-ASSOCIATED CANCERS
A substantial number of cancers are linked to a hormonal etiology
such as tumors of the breast, endometrium, ovary, prostate, testis,
and thyroid. Adipose tissue excess is thought to be related with
these types of tumors due to the abnormal levels of several hor-
mones encountered in obesity, most notably increased estrogen
levels (262, 263). Estrogen is a known growth factor with differ-
ent biosynthesis between pre- and post-menopausal women (264).
Pre-menopausal women mainly synthesize estrogens in the ovary,
however, after the menopause peripheral sites including adipose
tissue, are the primary source of estrogens. In this regard, for post-
menopausal women, significant increases in estrone, estradiol, and
free estradiol are associated with increasing BMI (262). Estro-
gen binds to at least three major classes of receptors, ER-α, ER-β,
and GPR30 (265) activating numerous growth-promoting genes,
including growth factors and growth-enhancing protooncogenes
such as c-fos and c-myc (266–268). The primary mediator of post-
menopausal estrogen biosynthesis is aromatase, which is found in
adipose tissue as well as tumor tissue itself (269). In the expand-
ing adipose tissue, this mechanism of production leads to a local
increase in estrogen levels favoring tumor development (15). Dif-
ferent meta-analysis indicated a higher risk of breast cancer in
post-menopausal women with high serum estrogen levels (270,
271). However, the role of blood levels of estrogen in obesity-
associated colon cancer is controversial. Evidence showed a worse
marked effect of obesity in men than women in the carcinogenesis
of colon cancer, pointing to a protective effect of estrogens, which
are increased in obesity (56).
In addition to excess estrogen, hyperplasia and carcinogenesis
may also stem from a decrease in circulating progesterone levels. In
obese women, lack of progesterone due to anovulation, similar to
that observed in the polycystic ovarian syndrome, may contribute
to endometrial cancer risk (272).
OBESITY-ASSOCIATED INSULIN RESISTANCE
Insulin is a key hormone involved in the control of glucose and
lipid homeostasis with insulin actions being mediated by a trans-
membrane insulin receptor, a heterotetrameric glycoprotein con-
sisting of two α-subunits and two β-subunits linked by disulfide
bonds (273). Insulin promotes cellular response through many
pathways, including PI3K/Akt signaling leading to AMPK activa-
tion. AMPK has been implicated in regulating cellular functions
including energy state, fuel metabolism, mitochondrial biogen-
esis, protein and ceramide synthesis, as well as cell growth and
proliferation (274). In addition, its activation was initially shown
to inhibit TNF-α-induced inflammation, insulin resistance, apop-
tosis, and oxidative stress. AMPK activity is diminished in adipose
tissue from severely obese subjects who are insulin resistant com-
pared to equally obese individuals who are insulin sensitive (275).
Studies evaluating insulin secretion, as reflected by C-peptide lev-
els, have pointed out a correlation between hyperinsulinemia and
poor clinical outcome and death in prostate cancer (276). A recent
study has shown that aldo–keto reductase 1B10, which plays a
critical role in tumor development and progression through pro-
moting lipogenesis and eliminating cytotoxic carbonyls, is induced
by insulin through the activator protein-1 (AP-1) signaling path-
way in human hepatocellular carcinoma cells (277). Most recent
reports have also suggested that insulin has mitogenic and anti-
apoptotic effects in endometrial cancer and that the activation
of insulin receptors and Akt is associated with more aggressive
features (278, 279).
Since insulin also acts as a growth factor, there are some mol-
ecules, called insulin-like peptides (ILPs), which can bind to the
insulin receptor and trigger intracellular responses similar to those
triggered by insulin. In humans, the most important ILPs are IGF-1
and IGF-2. The mitogenic and anti-apoptotic environment caused
by elevated levels of insulin and IGF-1 in obesity accelerates the
stepwise accumulation of mutations and, hence, favor carcino-
genesis (280). Studies evaluating IGF-1 circulating concentrations
and cancer risk show important effects on cancer development
and progression. Circulating IGF-1 binds mainly to the major
IGF-binding protein, IGFBP-3 (281). Results of early studies eval-
uating the risk of prostate (282), breast (283), colorectal (284),
and lung cancer (285) suggest that high circulating IGF-1 con-
centrations are associated with an increased risk, whereas high
IGFBP-3 concentrations are associated with a lower risk (286,
287). Associations between IGF-1, IGFBP-3, and cancer risk vary
by cancer site. Circulating concentrations of IGF-1 increase the
risk of non-smoking-related malignant diseases (288). Other ILPs,
like IGF-2, have also been proposed to have a relationship with
carcinogenesis (279).
HYPOXIA, ANGIOGENESIS, AND CANCER DEVELOPMENT
Adipose tissue presents an adequate exposure to nutrients and
oxygen due to the extensive capillary network surrounding each
adipocyte. However, there is substantial evidence that hypoxia
develops in adipose tissue as the tissue mass expands, and the
reduction in O2 concentrations is considered to underlie the
obesity-associated inflammatory response (289). Cancer may
be promoted by the hypoxic and angiogenic environment of
obese adipose tissue, in conjunction with the described elevated
circulating levels of cytokines existing in obese subjects (290).
Studies in hepatocellular carcinoma have shown a higher accu-
mulation of ATM in tumor regions poorly vascularized (291, 292).
Under low oxygen conditions, both tumor cells and macrophages
establish a proangiogenic program mediated by HIF-1, which is
a transcriptional activator complex constituted with two types of
subunits, an inducibleα subunit (HIF-1α, HIF-2α, or HIF-3α), and
the constitutively expressed HIF-1β subunit. Hypoxia stabilizes
HIF-1α, preventing its post-translational hydroxylation and con-
sequently proteasome-mediated degradation. In addition, hypoxia
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promotes HIF-1α association with HIF-1β, as well as cofactor
recruitment (293). HIF-1α is also transcriptionally regulated by
NF-κB (294). ATM adaptation to hypoxia is mediated by the
induction of HIF-1 and HIF-2-regulated genes, including VEGF,
fibroblast growth factor (FGF)-β, and IL-8, as well as glycolytic
enzymes (295). Furthermore, the HIF-1 pathway has been demon-
strated to play a role in macrophage recruitment and activation.
As suggested for NF-κB and STAT-3, HIF-1 might be a potential
target in hepatocellular carcinoma therapy (296). HIF-1 has been
also proposed as a key molecule implicated in tumor metastasis
(297, 298) and a possible metabolic target in cancer therapy (299–
301). Inflammatory molecules like TNF-α are also secreted by
adipose tissue in response to hypoxia and macrophage–monocyte
infiltration (280).
THERAPEUTIC STRATEGIES
Since obesity is a result of a prolonged positive energy balance,
caloric restriction and PA are key strategies to reduce BMI, fat
mass, and improve metabolic abnormalities. Although pharma-
ceutical approaches for obesity and T2D are used, the main pil-
lar of treatment is lifestyle changes. In this regard, it has been
recently reported that behaviors concordant with the Nutrition
and Physical Activity Cancer Prevention Guidelines are associated
with lower risk of total, breast, and colorectal cancers and lower
cancer-specific mortality in post-menopausal women (302).
PHYSICAL ACTIVITY
Sedentary behavior and insufficient PA are strongly related with
obesity and metabolic syndrome development. Animal studies
have shown metabolic beneficial effects of aerobic exercise train-
ing independent of dietary changes (303). However, it has been
demonstrated that the combination of PA and dietary interven-
tion is more effective than only an increase in PA (304). There are
evidences of benefits of physical exercise to normalize obesity-
altered lipid patterns (305, 306), improve glucose metabolism
(307), change the growth hormone/IGF-1 axis (308), and con-
sequently reduce the risk of obesity-associated comorbidities.
Studies in humans have also shown a direct relationship between
BMI, PA, and mortality with cancer (309). In a large cohort study
of middle-age women, both the excess of weight (considered as a
BMI≥ 25 kg/m2) and sedentary habits were significantly associ-
ated with an increased mortality. It has been estimated that excess
weight and physical inactivity could account for 31% of all prema-
ture deaths and 21% of deaths from cancer among non-smoking
women (310). A great variety of studies has reported the advan-
tages of PA in several types of cancer, such as breast (311, 312),
colon (313, 314), or prostate cancer (315).
DIET
Both epidemiological studies and experiments in animals suggest
that alterations in caloric intake or in the quality of the diet may
significantly influence the risk of cancer development and progres-
sion. A higher risk of cancer development related to diets rich in
calories, overabundant in alcohol and animal fats, and/or deficient
in vegetal products has been reported. By contrast, cancer risk was
lower in diets with a higher intake of fruit and vegetables. High-
fiber cereal consumption has also been linked to a reduced risk
of colorectal cancer (16, 316). Recently, the role of ω-3 polyun-
saturated fatty acids in cancer prevention has been highlighted
(317, 318). These fatty acids exert their effects by targeting differ-
ent stages of cancer development, including cell proliferation and
survival, inflammation, or angiogenesis (319, 320).
A cell-cycle regulation by nutrients has been shown in studies
on Saccharomyces cerevisiae. Growth experiments under glucose-
limited conditions suggested that coupling of circadian, metabolic,
and cell division cycles is essential for genome integrity (321).
However, the coupling of these cycles is highly dependent on
the experimental conditions and can be uncoupled under other
nutrient-limiting conditions (322). The relationship between
nutrient availability and genome alterations could play a role in
obesity-related cancer due to an abnormal energy state in obese
subjects. Therefore, aerobic glycolysis or the Warburg effect links
the high rate of glucose fermentation to cancer (323). Moreover,
sugar intake and consumption of sweet cakes and cookies have
been associated with increased risk of endometrial cancer (324).
Biological mechanisms whereby high-sugar foods consumption
might increase risk of cancer development are related to the devel-
opment of hyperglycemia, stimulation of insulin production, and
insulin resistance (325, 326).
Caloric restriction could be a strategy to prevent cancer by
reducing changes induced by obesity and general inflammatory
profile (327). In this regard, studies in prostate cancer and murine
prostate cancer models suggest that caloric restriction and weight
loss may reduce the risk of prostate cancer-specific mortality (71).
Positive effects of weight loss and PA have also been demonstrated
in colorectal cancer (55).
BARIATRIC SURGERY
When PA and dietary changes are not enough to reduce BMI,
bariatric surgery is a useful strategy to reduce excess of fat mass
and prevent weight gain in morbid obesity. There are different sur-
gical techniques that combine variable degrees of restriction and
malabsorption. Beneficial effects of bariatric surgery in reduc-
ing obesity-associated alterations have been largely described. A
clinical improvement in patients with T2D after bariatric surgery
procedures has been shown (328, 329). Noteworthy, there are
studies that suggest a preventive effect of bariatric surgery on
diabetes development (330). Positive effects over other comorbidi-
ties include OSA (331), dyslipidemia (332), hepatic fibrosis (333),
and cardiovascular risk (334, 335). Furthermore, there is evidence
showing that bariatric surgery-induced weight loss reduces cancer
risk in some retrospective cohort studies (336, 337). The mecha-
nisms that may lead to a reduced cancer incidence in subjects under
bariatric surgery include reduction in sex steroid plasma levels;
decreased circulating fatty acid,adipokines, and pro-inflammatory
cytokines levels; improvement in insulin sensitivity and reduction
of fat mass leading to a lower ectopic fat accumulation (338). The
Swedish Obese Subjects (SOS) study, a prospective and controlled
intervention trial involving 2,010 obese patients who underwent
bariatric surgery and 1,037 contemporaneously matched obese
subjects, found a significantly lower number of first-time can-
cers after inclusion in the surgery group (gastric banding, vertical
banded gastroplasty, and gastric bypass) than in the control group,
but only in women. It has been postulated that since gastric
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FIGURE 2 | Proposed mechanisms linking obesity and cancer. The excess
of adipose tissue, especially abdominal obesity, is related to changes in
circulating lipid concentrations, reactive oxygen species levels as well as
adipokine and hormone secretion profile. Obesity is also linked to adipocyte
hypertrophy and hypoxia, aggravating the inflammatory state. Therefore, the
adipose tissue-derived inflammatory cytokines, the production of angiogenic
factors by adipocytes, or infiltrating M1 macrophages that take place in
obesity together with the obesity-associated insulin resistance may promote
the stimulation of a microenvironment favorable for tumorigenesis. CRP,
C-reactive protein; HIF-1α, hypoxia-inducible factor-1α; IGF, insulin growth
factor; IGFBP, insulin-like growth factor-binding protein; IL, interleukin; MCP-1,
monocyte chemoattractant protein 1; MMP, matrix metalloproteinase; OPN,
osteopontin; PAI-1, plasminogen activator inhibitor-1; TGF-β, transforming
growth factor β; TNF-α, tumor necrosis factor α;YKL-40, chitinase-3-like protein.
bypass reduces hyperinsulinemia, this could also be a biological
mechanism by which bariatric surgery exerts protective effects on
cancer incidence (339). Future studies with larger patient num-
bers and longer follow-up periods are required to firmly establish
whether this might also have beneficial effects for men in the long
term (340).
CONCLUSION
Obesity is a potentially avoidable high prevalent risk factor for
developing different health problems including tumor develop-
ment. There are increasing evidences relating obesity and cancer,
with a well-established relationship between obesity and breast,
colorectal, prostate, or lung cancer among others. It has been
proposed that an important percentage of all cancer deaths may
be attributable to obesity. Due to the high prevalence and reper-
cussion of these conditions, the understanding of mechanisms of
obesity-associated tumorigenesis is an important objective in the
prevention and treatment of these pathologies. Future interven-
tions to reduce the prevalence of obesity are needed to prevent
cancer development in these patients. In this regard, it has been
shown that increased PA, healthy dietary habits, and bariatric
surgery may be appropriate to reduce cancer risk in obese patients.
In addition, a comprehensive approximation to the underlying
molecular mechanisms involved in obesity-related carcinogene-
sis may provide specific targets implicated in pathways by which
obesity leads to tumor progression. Reduction of inflammatory
signaling, improvement of insulin sensitivity, or counteracting
the hypoxia-inducible factors appears to be relevant pathways in
prevention of cancer development and reducing its progression
(Figure 2).
ACKNOWLEDGMENTS
This work was supported by Fondo de Investigación Sanitaria-
FEDER (PI11/02681, PI12/00515, PI13/00460) from the Spanish
Instituto de Salud Carlos III and by the Department of Health
(48/2011 and 58/2011) of the Gobierno de Navarra of Spain. Cen-
tro de Investigación Biomédica en Red de Fisiopatología de la
Obesidad y Nutrición is an initiative of the Instituto de Salud
Carlos III (Spain).
REFERENCES
1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends
in the distribution of body mass index among US adults, 1999-2010. JAMA
(2012) 307:491–7. doi:10.1001/jama.2012.39
www.frontiersin.org May 2014 | Volume 5 | Article 65 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pérez-Hernández et al. Dysregulation of adipose tissue and cancer development
2. Gómez-Ambrosi J, Silva C, Galofré JC, Escalada J, Santos S, Millán D, et al.
Body mass index classification misses subjects with increased cardiometa-
bolic risk factors related to elevated adiposity. Int J Obes (2012) 36:286–94.
doi:10.1038/ijo.2011.100
3. Frühbeck G. Obesity: screening for the evident in obesity. Nat Rev Endocrinol
(2012) 8:570–2. doi:10.1038/nrendo.2012.165
4. Frühbeck G, Toplak H, Woodward E, Yumuk V, Maislos M, Oppert JM. Obe-
sity: the gateway to ill health – an EASO position statement on a rising public
health, clinical and scientific challenge in Europe. Obes Facts (2013) 6:117–20.
doi:10.1159/000350627
5. Kral JG, Kava RA, Catalano PM, Moore BJ. Severe obesity: the neglected epi-
demic. Obes Facts (2012) 5:254–69. doi:10.1159/000338566
6. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Preva-
lence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA
(2003) 289:76–9. doi:10.1001/jama.289.1.76
7. Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology (2006)
130:1848–52. doi:10.1053/j.gastro.2006.03.041
8. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity
and the metabolic syndrome. Proc Nutr Soc (2010) 69:211–20. doi:10.1017/
S0029665110000030
9. Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am
(2010) 39:57–68. doi:10.1016/j.gtc.2009.12.001
10. de Sousa AG, Cercato C, Mancini MC, Halpern A. Obesity and obstructive
sleep apnea-hypopnea syndrome. Obes Rev (2008) 9:340–54. doi:10.1111/j.
1467-789X.2008.00478.x
11. Campo A, Frühbeck G, Zulueta JJ, Iriarte J, Seijo LM, Alcaide AB, et al. Hyper-
leptinaemia, respiratory drive and hypercapnic response in obese patients. Eur
Respir J (2007) 30:223–31. doi:10.1183/09031936.00115006
12. Gómez-Ambrosi J, Salvador J, Paramo JA, Orbe J, de Irala J, Diez-Caballero
A, et al. Involvement of leptin in the association between percentage of
body fat and cardiovascular risk factors. Clin Biochem (2002) 35:315–20.
doi:10.1016/S0009-9120(02)00320-X
13. Landsberg L,Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-
related hypertension: pathogenesis, cardiovascular risk, and treatment – a posi-
tion paper of the obesity society and the American society of hypertension.
Obesity (2013) 21:8–24. doi:10.1002/oby.20181
14. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with car-
diovascular disease. Nature (2006) 444:875–80. doi:10.1038/nature05487
15. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence
and proposed mechanisms. Nat Rev Cancer (2004) 4:579–91. doi:10.1038/
nrc1408
16. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes
(2013) 2013:291546. doi:10.1155/2013/291546
17. Hursting SD. Minireview: the year in obesity and cancer. Mol Endocrinol (2012)
26:1961–6. doi:10.1210/me.2012-1283
18. Louie SM, Roberts LS, Nomura DK. Mechanisms linking obesity and cancer.
Biochim Biophys Acta (2013) 1831:1499–508. doi:10.1016/j.bbalip.2013.02.008
19. Sundaram S, Johnson AR, Makowski L. Obesity, metabolism and the microen-
vironment: links to cancer. J Carcinog (2013) 12:19. doi:10.4103/1477-3163.
119606
20. Aleman JO, Eusebi LH, Ricciardiello L, Patidar K, Sanyal AJ, Holt PR. Mech-
anisms of obesity-induced gastrointestinal neoplasia. Gastroenterology (2013)
146:357–73. doi:10.1053/j.gastro.2013.11.051
21. Calle EE, Thun MJ. Obesity and cancer. Oncogene (2004) 23:6365–78. doi:10.
1038/sj.onc.1207751
22. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al. Hepa-
tocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary
team. J Hepatol (2014) 60:110–7. doi:10.1016/j.jhep.2013.08.011
23. Kitahara CM, Berndt SI, de Gonzalez AB, Coleman HG, Schoen RE, Hayes RB,
et al. Prospective investigation of body mass index, colorectal adenoma, and
colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening
trial. J Clin Oncol (2013) 31:2450–9. doi:10.1200/JCO.2012.48.4691
24. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statis-
tics. CA Cancer J Clin (2011) 61:69–90. doi:10.3322/caac.20107
25. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin
(2013) 63:11–30. doi:10.3322/caac.21166
26. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, et al.
Recent trends in incidence of five common cancers in 26 European countries
since 1988: analysis of the European cancer observatory. Eur J Cancer (2013).
doi:10.1016/j.ejca.2013.09.002
27. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber
H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40
countries in 2012. Eur J Cancer (2013) 49:1374–403. doi:10.1016/j.ejca.2012.
12.027
28. de Vries E, Soerjomataram I, Lemmens VE, Coebergh JW, Barendregt JJ, Oen-
ema A, et al. Lifestyle changes and reduction of colon cancer incidence in
Europe: a scenario study of physical activity promotion and weight reduction.
Eur J Cancer (2010) 46:2605–16. doi:10.1016/j.ejca.2010.07.040
29. Lieberman D. Colorectal cancer screening: practice guidelines. Dig Dis (2012)
30(Suppl 2):34–8. doi:10.1159/000341891
30. Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat
Rev Urol (2013) 10:38–48. doi:10.1038/nrurol.2013.84
31. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening
in the United States, 2013: a review of current American cancer society guide-
lines, current issues in cancer screening, and new guidance on cervical can-
cer screening and lung cancer screening. CA Cancer J Clin (2013) 63:88–105.
doi:10.3322/caac.21174
32. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity,
and mortality from cancer in a prospectively studied cohort of U.S. adults.
N Engl J Med (2003) 348:1625–38. doi:10.1056/NEJMoa021423
33. Chang SH, Pollack LM, Colditz GA. Obesity, mortality, and life years lost asso-
ciated with breast cancer in nonsmoking US women, national health inter-
view survey, 1997-2000. Prev Chronic Dis (2013) 10:E186. doi:10.5888/pcd10.
130112
34. Ghaem Maralani H, Tai BC, Wong TY, Tai ES, Li J, Wang JJ, et al. The prog-
nostic role of body mass index on mortality amongst the middle-aged and
elderly: a competing risk analysis. Diabetes Res Clin Pract (2013) 103(1):42–50.
doi:10.1016/j.diabres.2013.11.025
35. Hainer V, Aldhoon-Hainerova I. Obesity paradox does exist. Diabetes Care
(2013) 36(Suppl 2):S276–81. doi:10.2337/dcS13-2023
36. Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, et al. The
impact of obesity on the short-term and long-term outcomes after percuta-
neous coronary intervention: the obesity paradox? J Am Coll Cardiol (2002)
39:578–84. doi:10.1016/S0735-1097(01)01802-2
37. Shah R, Gayat E, Januzzi JL Jr, Sato N, Cohen-Solal A, Disomma S, et al.
Body mass index and mortality in acutely decompensated heart failure across
the world: a global obesity paradox. J Am Coll Cardiol (2014) 63:778–85.
doi:10.1016/j.jacc.2013.09.072
38. Heymsfield SB, Cefalu WT. Does body mass index adequately convey a patient’s
mortality risk? JAMA (2013) 309:87–8. doi:10.1001/jama.2012.185445
39. Montazeri A, Sadighi J, Farzadi F, Maftoon F, Vahdaninia M, Ansari M, et al.
Weight, height, body mass index and risk of breast cancer in postmenopausal
women: a case-control study. BMC Cancer (2008) 8:278. doi:10.1186/1471-
2407-8-278
40. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M,
et al. Relationship between obesity and pathologic response to neoadjuvant
chemotherapy among women with operable breast cancer. J Clin Oncol (2008)
26:4072–7. doi:10.1200/JCO.2007.14.4527
41. Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, et al.
Effect of obesity and other lifestyle factors on mortality in women with breast
cancer. Int J Cancer (2008) 123:2188–94. doi:10.1002/ijc.23747
42. Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi
GN, et al. Prognostic value of body mass index in locally advanced breast
cancer. Clin Cancer Res (2008) 14:1718–25. doi:10.1158/1078-0432.CCR-07-
1479
43. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity
an independent prognosis factor in woman breast cancer? Breast Cancer Res
Treat (2008) 111:329–42. doi:10.1007/s10549-007-9785-3
44. Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI,
et al. Weight gain prior to diagnosis and survival from breast cancer. Cancer
Epidemiol Biomarkers Prev (2007) 16:1803–11. doi:10.1158/1055-9965.EPI-
06-0889
45. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, et al.
Body size and breast cancer risk: findings from the European prospective inves-
tigation into cancer and nutrition (EPIC). Int J Cancer (2004) 111:762–71.
doi:10.1002/ijc.20315
Frontiers in Endocrinology | Cancer Endocrinology May 2014 | Volume 5 | Article 65 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pérez-Hernández et al. Dysregulation of adipose tissue and cancer development
46. Mellemkjaer L, Bigaard J, Tjonneland A, Christensen J, Thomsen B, Johansen
C, et al. Body composition and breast cancer in postmenopausal women: a
Danish prospective cohort study. Obesity (2006) 14:1854–62. doi:10.1038/oby.
2006.214
47. Boyd NF, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, et al. Body size, mam-
mographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev
(2006) 15:2086–92. doi:10.1158/1055-9965.EPI-05-0762
48. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index
and incidence of cancer: a systematic review and meta-analysis of prospective
observational studies. Lancet (2008) 371:569–78. doi:10.1016/S0140-6736(08)
60269-X
49. Andrieu N, Launoy G, Guillois R, Ory-Paoletti C, Gignoux M. Familial rela-
tive risk of colorectal cancer: a population-based study. Eur J Cancer (2003)
39:1904–11. doi:10.1016/S0959-8049(03)00420-9
50. Kim Y, Lee S. An association between colonic adenoma and abdominal obe-
sity: a cross-sectional study. BMC Gastroenterol (2009) 9:4. doi:10.1186/1471-
230X-9-4
51. Thygesen LC, Gronbaek M, Johansen C, Fuchs CS, Willett WC, Giovannucci E.
Prospective weight change and colon cancer risk in male US health profession-
als. Int J Cancer (2008) 123:1160–5. doi:10.1002/ijc.23612
52. Guffey CR, Fan D, Singh UP, Murphy EA. Linking obesity to colorectal can-
cer: recent insights into plausible biological mechanisms. Curr Opin Clin Nutr
Metab Care (2013) 16:595–600. doi:10.1097/MCO.0b013e328362d10b
53. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, et al. Obesity and risk of colorectal
cancer: a systematic review of prospective studies. PLoS One (2013) 8:e53916.
doi:10.1371/journal.pone.0053916
54. Larsson SC, Bergkvist L, Wolk A. High-fat dairy food and conjugated linoleic
acid intakes in relation to colorectal cancer incidence in the Swedish mammog-
raphy cohort. Am J Clin Nutr (2005) 82:894–900.
55. Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut (2013)
62:933–47. doi:10.1136/gutjnl-2013-304701
56. Chen J, Iverson D. Estrogen in obesity-associated colon cancer: friend or foe?
Protecting postmenopausal women but promoting late-stage colon cancer.
Cancer Causes Control (2012) 23:1767–73. doi:10.1007/s10552-012-0066-z
57. Ben Q, An W, Jiang Y, Zhan X, Du Y, Cai QC, et al. Body mass index increases
risk for colorectal adenomas based on meta-analysis. Gastroenterology (2012)
142:762–72. doi:10.1053/j.gastro.2011.12.050
58. Lin J, Zhang SM, Cook NR, Rexrode KM, Lee IM, Buring JE. Body mass index
and risk of colorectal cancer in women (United States). Cancer Causes Control
(2004) 15:581–9. doi:10.1023/B:CACO.0000036168.23351.f1
59. Yoshimoto S, Loo TM,Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-
induced gut microbial metabolite promotes liver cancer through senescence
secretome. Nature (2013) 499:97–101. doi:10.1038/nature12347
60. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. Inter-
national variation in prostate cancer incidence and mortality rates. Eur Urol
(2012) 61:1079–92. doi:10.1016/j.eururo.2012.02.054
61. Bergström A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable
cause of cancer in Europe. Int J Cancer (2001) 91:421–30. doi:10.1002/1097-
0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T
62. MacInnis RJ, English DR. Body size and composition and prostate cancer risk:
systematic review and meta-regression analysis. Cancer Causes Control (2006)
17:989–1003. doi:10.1007/s10552-006-0074-y
63. Spangler E, Zeigler-Johnson CM, Coomes M, Malkowicz SB, Wein A, Rebbeck
TR. Association of obesity with tumor characteristics and treatment failure
of prostate cancer in African-American and European American men. J Urol
(2007) 178:1939–44. doi:10.1016/j.juro.2007.07.021
64. Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund
A, et al. Body size and prostate cancer: a 20-year follow-up study among
135006 Swedish construction workers. J Natl Cancer Inst (1997) 89:385–9.
doi:10.1093/jnci/89.5.385
65. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, et al. Obe-
sity, adipokines, and prostate cancer in a prospective population-based study.
Cancer Epidemiol Biomarkers Prev (2006) 15:1331–5. doi:10.1158/1055-9965.
EPI-06-0082
66. Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate can-
cer: a follow-up of 950000 Norwegian men. Br J Cancer (2003) 89:1237–42.
doi:10.1038/sj.bjc.6601206
67. Porter MP, Stanford JL. Obesity and the risk of prostate cancer. Prostate (2005)
62:316–21. doi:10.1002/pros.20121
68. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al.
Obesity, diabetes, and risk of prostate cancer: results from the prostate
cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 15:1977–83.
doi:10.1158/1055-9965.EPI-06-0477
69. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, et al.
Body mass index, weight change, and risk of prostate cancer in the cancer pre-
vention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev (2007)
16:63–9. doi:10.1158/1055-9965.EPI-06-0754
70. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al.
Prospective study of adiposity and weight change in relation to prostate cancer
incidence and mortality. Cancer (2007) 109:675–84. doi:10.1002/cncr.22443
71. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the
evidence. Eur Urol (2013) 63:800–9. doi:10.1016/j.eururo.2012.11.013
72. Yang Y, Dong J, Sun K, Zhao L, Zhao F, Wang L, et al. Obesity and inci-
dence of lung cancer: a meta-analysis. Int J Cancer (2013) 132:1162–9.
doi:10.1002/ijc.27719
73. El-Zein M, Parent ME, Rousseau MC. Comments on a recent meta-analysis:
obesity and lung cancer. Int J Cancer (2013) 132:1962–3. doi:10.1002/ijc.27854
74. Kabat GC, Wynder EL. Body mass index and lung cancer risk. Am J Epidemiol
(1992) 135:769–74.
75. Khan N, Afaq F, Mukhtar H. Lifestyle as risk factor for cancer: evidence
from human studies. Cancer Lett (2010) 293:133–43. doi:10.1016/j.canlet.2009.
12.013
76. Kabat GC, Kim M, Hunt JR, Chlebowski RT, Rohan TE. Body mass index
and waist circumference in relation to lung cancer risk in the women’s health
initiative. Am J Epidemiol (2008) 168:158–69. doi:10.1093/aje/kwn109
77. Kanashiki M, Sairenchi T, Saito Y, Ishikawa H, Satoh H, Sekizawa K. Body
mass index and lung cancer: a case-control study of subjects participating in
a mass-screening program. Chest (2005) 128:1490–6. doi:10.1378/chest.128.3.
1490
78. Kabat GC, Miller AB, Rohan TE. Body mass index and lung cancer risk in
women. Epidemiology (2007) 18:607–12. doi:10.1097/EDE.0b013e31812713d1
79. Ntikoudi E, Kiagia M, Boura P, Syrigos KN. Hormones of adipose tissue
and their biologic role in lung cancer. Cancer Treat Rev (2014) 40:22–30.
doi:10.1016/j.ctrv.2013.06.005
80. Bray GA, Popkin BM. Dietary sugar and body weight: have we reached a crisis
in the epidemic of obesity and diabetes? Health be damned! Pour on the sugar.
Diabetes Care (2014) 37:950–6. doi:10.2337/dc13-2085
81. Ludwig DS, Peterson KE, Gortmaker SL. Relation between consumption of
sugar-sweetened drinks and childhood obesity: a prospective, observational
analysis. Lancet (2001) 357:505–8. doi:10.1016/S0140-6736(00)04041-1
82. Frühbeck G, Becerril S, Sáinz N, Garrastachu P, García-Velloso MJ. BAT:
a new target for human obesity? Trends Pharmacol Sci (2009) 30:387–96.
doi:10.1016/j.tips.2009.05.003
83. Catalán V, Gómez-Ambrosi J, Rodríguez A, Salvador J, Frühbeck G. Adipokines
in the treatment of diabetes mellitus and obesity. Expert Opin Pharmacother
(2009) 10:239–54. doi:10.1517/14656560802618811
84. Falcao-Pires I, Castro-Chaves P, Miranda-Silva D, Lourenco AP, Leite-Moreira
AF. Physiological, pathological and potential therapeutic roles of adipokines.
Drug Discov Today (2012) 17:880–9. doi:10.1016/j.drudis.2012.04.007
85. Rodríguez A, Catalán V, Gómez-Ambrosi J, Frühbeck G. Visceral and sub-
cutaneous adiposity: are both potential therapeutic targets for tackling
the metabolic syndrome? Curr Pharm Des (2007) 13:2169–75. doi:10.2174/
138161207781039599
86. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al.
Abdominal visceral and subcutaneous adipose tissue compartments: associa-
tion with metabolic risk factors in the Framingham Heart Study. Circulation
(2007) 116:39–48. doi:10.1161/CIRCULATIONAHA.106.675355
87. Koster A, Stenholm S, Alley DE, Kim LJ, Simonsick EM, Kanaya AM,
et al. Body fat distribution and inflammation among obese older adults with
and without metabolic syndrome. Obesity (2010) 18:2354–61. doi:10.1038/
oby.2010.86
88. Bjorntorp P. The associations between obesity, adipose tissue distribution and
disease. Acta Med Scand Suppl (1988) 723:121–34.
89. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to
its source. Cell (2007) 131:242–56. doi:10.1016/j.cell.2007.10.004
90. Frühbeck G, Sesma P, Burrell MA. PRDM16: the interconvertible
adipo-myocyte switch. Trends Cell Biol (2009) 19:141–6. doi:10.1016/j.tcb.
2009.01.007
www.frontiersin.org May 2014 | Volume 5 | Article 65 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pérez-Hernández et al. Dysregulation of adipose tissue and cancer development
91. Virtanen KA, Lidell ME, Orava J, Heglind M,Westergren R, Niemi T, et al. Func-
tional brown adipose tissue in healthy adults. N Engl J Med (2009) 360:1518–25.
doi:10.1056/NEJMoa0808949
92. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, et al. Iden-
tification and importance of brown adipose tissue in adult humans. N Engl
J Med (2009) 360:1509–17. doi:10.1056/NEJMoa0810780
93. Feng B, Zhang T, Xu H. Human adipose dynamics and metabolic health. Ann
N Y Acad Sci (2013) 1281:160–77. doi:10.1111/nyas.12009
94. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological
significance. Physiol Rev (2004) 84:277–359. doi:10.1152/physrev.00015.2003
95. Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ (1997)
315:1219–22. doi:10.1136/bmj.315.7117.1219
96. Tsoli M, Moore M, Burg D, Painter A, Taylor R, Lockie SH, et al. Activation
of thermogenesis in brown adipose tissue and dysregulated lipid metabo-
lism associated with cancer cachexia in mice. Cancer Res (2012) 72:4372–82.
doi:10.1158/0008-5472.CAN-11-3536
97. Wu J, Cohen P, Spiegelman BM. Adaptive thermogenesis in adipocytes: is beige
the new brown? Genes Dev (2013) 27:234–50. doi:10.1101/gad.211649.112
98. Virtue S, Vidal-Puig A. Adipose tissue expandability, lipotoxicity and the
metabolic syndrome – an allostatic perspective. Biochim Biophys Acta (2010)
1801:338–49. doi:10.1016/j.bbalip.2009.12.006
99. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al.
Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest
(1996) 97:2859–65. doi:10.1172/JCI118742
100. Rebrin K, Steil GM, Getty L, Bergman RN. Free fatty acid as a link in the
regulation of hepatic glucose output by peripheral insulin. Diabetes (1995)
44:1038–45. doi:10.2337/diabetes.44.9.1038
101. Hennes MM, Shrago E, Kissebah AH. Receptor and postreceptor effects of free
fatty acids (FFA) on hepatocyte insulin dynamics. Int J Obes (1990) 14:831–41.
102. Hunt DA, Lane HM, Zygmont ME, Dervan PA, Hennigar RA. MRNA stability
and overexpression of fatty acid synthase in human breast cancer cell lines.
Anticancer Res (2007) 27:27–34.
103. Gansler TS, Hardman W III, Hunt DA, Schaffel S, Hennigar RA. Increased
expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts
shorter survival. Hum Pathol (1997) 28:686–92. doi:10.1016/S0046-8177(97)
90177-5
104. Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase
inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice.
Oncogene (2005) 24:39–46. doi:10.1038/sj.onc.1208174
105. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, et al. Fatty acid
synthase polymorphisms, tumor expression, body mass index, prostate cancer
risk, and survival. J Clin Oncol (2010) 28:3958–64. doi:10.1200/JCO.2009.27.
0793
106. Fernández-Real JM, Menéndez JA, Moreno-Navarrete JM, Bluher M, Vazquez-
Martín A, Vazquez MJ, et al. Extracellular fatty acid synthase: a possible surro-
gate biomarker of insulin resistance. Diabetes (2010) 59:1506–11. doi:10.2337/
db09-1756
107. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacyl-
glycerol lipase regulates a fatty acid network that promotes cancer pathogenesis.
Cell (2010) 140:49–61. doi:10.1016/j.cell.2009.11.027
108. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zill-
hardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide
energy for rapid tumor growth. Nat Med (2011) 17:1498–503. doi:10.1038/
nm.2492
109. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose
tissue. J Clin Invest (2003) 112:1785–8. doi:10.1172/JCI200320514
110. Catalán V, Gómez-Ambrosi J, Rodríguez A, Frühbeck G. Role of extracellular
matrix remodelling in adipose tissue pathophysiology: relevance in the devel-
opment of obesity. Histol Histopathol (2012) 27:1515–28.
111. Medzhitov R. Origin and physiological roles of inflammation. Nature (2008)
454:428–35. doi:10.1038/nature07201
112. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the
end. Nat Immunol (2005) 6:1191–7. doi:10.1038/ni1276
113. Divoux A, Tordjman J, Lacasa D, Veyrie N, Hugol D, Aissat A, et al. Fibrosis in
human adipose tissue: composition, distribution, and link with lipid metabo-
lism and fat mass loss. Diabetes (2010) 59:2817–25. doi:10.2337/db10-0585
114. Hotamisligil GS. Inflammation and metabolic disorders. Nature (2006)
444:860–7. doi:10.1038/nature05485
115. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, et al.
CD8+ effector T cells contribute to macrophage recruitment and adipose tissue
inflammation in obesity. Nat Med (2009) 15:914–20. doi:10.1038/nm.1964
116. Nishimura S, Manabe I, Nagasaki M, Hosoya Y, Yamashita H, Fujita H,
et al. Adipogenesis in obesity requires close interplay between differentiat-
ing adipocytes, stromal cells, and blood vessels. Diabetes (2007) 56:1517–26.
doi:10.2337/db06-1749
117. Suganami T, Ogawa Y. Adipose tissue macrophages: their role in adipose tissue
remodeling. J Leukoc Biol (2010) 88:33–9. doi:10.1189/jlb.0210072
118. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet
(2001) 357:539–45. doi:10.1016/S0140-6736(00)04046-0
119. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420:860–7.
doi:10.1038/nature01322
120. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflamma-
tion in the initiation and promotion of malignant disease. Cancer Cell (2005)
7:211–7. doi:10.1016/j.ccr.2005.02.013
121. Karin M. Inflammation and cancer: the long reach of Ras. Nat Med (2005)
11:20–1. doi:10.1038/nm0105-20
122. Karin M. Nuclear factor-κB in cancer development and progression. Nature
(2006) 441:431–6. doi:10.1038/nature04870
123. Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity
and cancer: an inflammatory issue. Ann N Y Acad Sci (2011) 1229:45–52.
doi:10.1111/j.1749-6632.2011.06096.x
124. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al.
Prognostic value of intratumoral natural killer cells in gastric carcinoma.
Cancer (2000) 88:577–83. doi:10.1002/(SICI)1097-0142(20000201)88:3<577:
:AID-CNCR13>3.0.CO;2-V
125. Ribatti D, Ennas MG,Vacca A, Ferreli F, Nico B, Orru S, et al. Tumor vascularity
and tryptase-positive mast cells correlate with a poor prognosis in melanoma.
Eur J Clin Invest (2003) 33:420–5. doi:10.1046/j.1365-2362.2003.01152.x
126. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vas-
cular density and focal macrophage infiltration in invasive carcinoma of the
breast. Br J Cancer (1999) 79:991–5. doi:10.1038/sj.bjc.6690158
127. Catalán V, Gómez-Ambrosi J, Rodríguez A, Frühbeck G. Adipose tissue immu-
nity and cancer. Front Physiol (2013) 4:275. doi:10.3389/fphys.2013.00275
128. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr.
Obesity is associated with macrophage accumulation in adipose tissue. J Clin
Invest (2003) 112:1796–808. doi:10.1172/JCI19246
129. Mayi TH, Daoudi M, Derudas B, Gross B, Bories G, Wouters K, et al. Human
adipose tissue macrophages display activation of cancer-related pathways. J Biol
Chem (2012) 287:21904–13. doi:10.1074/jbc.M111.315200
130. Ribeiro R, Monteiro C, Catalán V, Hu P, Cunha V, Rodríguez A, et al. Obesity
and prostate cancer: gene expression signature of human periprostatic adipose
tissue. BMC Med (2012) 10:108. doi:10.1186/1741-7015-10-108
131. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F, et al.
Up-regulation of the novel proinflammatory adipokines lipocalin-2, chitinase-
3 like-1 and osteopontin as well as angiogenic-related factors in visceral adi-
pose tissue of patients with colon cancer. J Nutr Biochem (2011) 22:634–41.
doi:10.1016/j.jnutbio.2010.04.015
132. Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated
macrophages in neoplastic progression and immune surveillance. Immunol Rev
(2008) 222:155–61. doi:10.1111/j.1600-065X.2008.00607.x
133. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein
RA, et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in
joint autoimmune inflammation. J Exp Med (2003) 198:1951–7. doi:10.1084/
jem.20030896
134. Smith AM, Rahman FZ, Hayee B, Graham SJ, Marks DJ, Sewell GW, et al. Disor-
dered macrophage cytokine secretion underlies impaired acute inflammation
and bacterial clearance in Crohn’s disease. J Exp Med (2009) 206:1883–97.
doi:10.1084/jem.20091233
135. Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y, et al. Chronic
polyarthritis caused by mammalian DNA that escapes from degradation in
macrophages. Nature (2006) 443:998–1002. doi:10.1038/nature05245
136. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage sub-
sets. Nat Rev Immunol (2011) 11:723–37. doi:10.1038/nri3073
137. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance.
Annu Rev Physiol (2010) 72:219–46. doi:10.1146/annurev-physiol-021909-
135846
Frontiers in Endocrinology | Cancer Endocrinology May 2014 | Volume 5 | Article 65 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pérez-Hernández et al. Dysregulation of adipose tissue and cancer development
138. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation.
Nature (2008) 454:436–44. doi:10.1038/nature07205
139. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander
to major culprit. Nat Rev Cancer (2002) 2:301–10. doi:10.1038/nrc780
140. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the match-
maker. Nat Immunol (2011) 12:715–23. doi:10.1038/ni.2060
141. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al.
The inflammatory cytokine tumor necrosis factor-α generates an autocrine
tumor-promoting network in epithelial ovarian cancer cells. Cancer Res (2007)
67:585–92. doi:10.1158/0008-5472.CAN-06-2941
142. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gen-
der disparity in liver cancer due to sex differences in MyD88-dependent IL-6
production. Science (2007) 317:121–4. doi:10.1126/science.1140485
143. Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S, et al. Activated
macrophages promote Wnt signalling through tumour necrosis factor-α in
gastric tumour cells. EMBO J (2008) 27:1671–81. doi:10.1038/emboj.2008.105
144. Schmieder A, Michel J, Schonhaar K, Goerdt S, Schledzewski K. Differentiation
and gene expression profile of tumor-associated macrophages. Semin Cancer
Biol (2012) 22:289–97. doi:10.1016/j.semcancer.2012.02.002
145. Cintra DE, Pauli JR, Araujo EP, Moraes JC, de Souza CT, Milanski M, et al.
Interleukin-10 is a protective factor against diet-induced insulin resistance in
liver. J Hepatol (2008) 48:628–37. doi:10.1016/j.jhep.2007.12.017
146. Tateya S, Kim F, Tamori Y. Recent advances in obesity-induced inflam-
mation and insulin resistance. Front Endocrinol (Lausanne) (2013) 4:93.
doi:10.3389/fendo.2013.00093
147. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch
in adipose tissue macrophage polarization. J Clin Invest (2007) 117:175–84.
doi:10.1172/JCI29881
148. Nakanishi Y, Nakatsuji M, Seno H, Ishizu S, Akitake-Kawano R, Kanda K,
et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages
from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis (2011) 32:1333–9.
doi:10.1093/carcin/bgr128
149. Poulain-Godefroy O, Lecoeur C, Pattou F, Frühbeck G, Froguel P. Inflamma-
tion is associated with a decrease of lipogenic factors in omental fat in women.
Am J Physiol Regul Integr Comp Physiol (2008) 295:R1–7. doi:10.1152/ajpregu.
00926.2007
150. Zhou D, Huang C, Lin Z, Zhan S, Kong L, Fang C, et al. Macrophage
polarization and function with emphasis on the evolving roles of coordi-
nated regulation of cellular signaling pathways. Cell Signal (2013) 26:192–7.
doi:10.1016/j.cellsig.2013.11.004
151. Frühbeck G. The Sir David Cuthbertson Medal Lecture. Hunting for new
pieces to the complex puzzle of obesity. Proc Nutr Soc (2006) 65:329–47.
doi:10.1079/PNS2006510
152. Frühbeck G, Gómez-Ambrosi J. Rationale for the existence of additional adi-
postatic hormones. FASEB J (2001) 15:1996–2006. doi:10.1096/fj.00-0829hyp
153. Frühbeck G, Gómez-Ambrosi J, Salvador J. Leptin-induced lipolysis opposes
the tonic inhibition of endogenous adenosine in white adipocytes. FASEB J
(2001) 15:333–40. doi:10.1096/fj.00-0249com
154. CatalánV, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F,ValentiV, et al.
Increased levels of calprotectin in obesity are related to macrophage content:
impact on inflammation and effect of weight loss. Mol Med (2011) 17:1157–67.
doi:10.2119/molmed.2011.00144
155. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F, Valenti V,
et al. Increased circulating and visceral adipose tissue expression levels of YKL-
40 in obesity-associated type 2 diabetes are related to inflammation: impact
of conventional weight loss and gastric bypass. J Clin Endocrinol Metab (2011)
96:200–9. doi:10.1210/jc.2010-0994
156. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F, Valentí V,
et al. Increased tenascin C and toll-like receptor 4 levels in visceral adipose
tissue as a link between inflammation and extracellular matrix remodeling in
obesity. J Clin Endocrinol Metab (2012) 97:E1880–9. doi:10.1210/jc.2012-1670
157. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F, Valentí V,
et al. Increased levels of chemerin and its receptor, chemokine-like receptor-
1, in obesity are related to inflammation: tumor necrosis factor-α stimulates
mRNA levels of chemerin in visceral adipocytes from obese patients. Surg Obes
Relat Dis (2013) 9:306–14. doi:10.1016/j.soard.2011.11.001
158. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F, Valentí
V, et al. Six-transmembrane epithelial antigen of prostate 4 and neutrophil
gelatinase-associated lipocalin expression in visceral adipose tissue is related to
iron status and inflammation in human obesity. Eur J Nutr (2013) 52:1587–95.
doi:10.1007/s00394-012-0464-8
159. Frühbeck G. Obesity: aquaporin enters the picture. Nature (2005) 438:436–7.
doi:10.1038/438436b
160. Gómez-Ambrosi J, Catalán V, Ramírez B, Rodríguez A, Colina I, Silva C,
et al. Plasma osteopontin levels and expression in adipose tissue are increased
in obesity. J Clin Endocrinol Metab (2007) 92:3719–27. doi:10.1210/jc.2007-
0349
161. Gómez-Ambrosi J, Frühbeck G. Do resistin and resistin-like molecules also
link obesity to inflammatory diseases? Ann Intern Med (2001) 135:306–7.
doi:10.7326/0003-4819-135-4-200108210-00030
162. Lancha A, Frühbeck G, Gómez-Ambrosi J. Peripheral signalling involved in
energy homeostasis control. Nutr Res Rev (2012) 25:223–48. doi:10.1017/
S0954422412000145
163. Moreno-Navarrete JM, Catalán V, Whyte L, Diaz-Arteaga A, Vazquez-Martinez
R, Rotellar F, et al. The l-α-lysophosphatidylinositol/GPR55 system and its
potential role in human obesity. Diabetes (2012) 61:281–91. doi:10.2337/db11-
0649
164. Muruzábal FJ, Frühbeck G, Gómez-Ambrosi J, Archanco M, Burrell MA.
Immunocytochemical detection of leptin in non-mammalian vertebrate stom-
ach. Gen Comp Endocrinol (2002) 128:149–52. doi:10.1016/S0016-6480(02)
00072-2
165. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum pro-
tein similar to C1q, produced exclusively in adipocytes. J Biol Chem (1995)
270:26746–9. doi:10.1074/jbc.270.45.26746
166. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired mul-
timerization of human adiponectin mutants associated with diabetes. Mole-
cular structure and multimer formation of adiponectin. J Biol Chem (2003)
278:40352–63. doi:10.1074/jbc.M300365200
167. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev
(2005) 26:439–51. doi:10.1210/er.2005-0005
168. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin
and adiponectin receptors in insulin resistance, diabetes, and the metabolic
syndrome. J Clin Invest (2006) 116:1784–92. doi:10.1172/JCI29126
169. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess
T, et al. Structure-function studies of the adipocyte-secreted hormone
Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity.
J Biol Chem (2003) 278:9073–85. doi:10.1074/jbc.M207198200
170. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin
expression from human adipose tissue: relation to obesity, insulin resis-
tance, and tumor necrosis factor-α expression. Diabetes (2003) 52:1779–85.
doi:10.2337/diabetes.52.7.1779
171. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic
review. Br J Cancer (2006) 94:1221–5. doi:10.1038/sj.bjc.6603051
172. Hillenbrand A, Fassler J, Huber N, Xu P, Henne-Bruns D, Templin M, et al.
Changed adipocytokine concentrations in colorectal tumor patients and mor-
bidly obese patients compared to healthy controls. BMC Cancer (2012) 12:545.
doi:10.1186/1471-2407-12-545
173. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma
adiponectin levels and risk of colorectal cancer in men: a prospective study.
J Natl Cancer Inst (2005) 97:1688–94. doi:10.1093/jnci/dji376
174. Moon HS, Chamberland JP, Aronis K, Tseleni-Balafouta S, Mantzoros CS.
Direct role of adiponectin and adiponectin receptors in endometrial cancer:
in vitro and ex vivo studies in humans. Mol Cancer Ther (2011) 10:2234–43.
doi:10.1158/1535-7163.MCT-11-0545
175. Liu LY, Wang M, Ma ZB, Yu LX, Zhang Q, Gao DZ, et al. The role of
adiponectin in breast cancer: a meta-analysis. PLoS One (2013) 8:e73183.
doi:10.1371/journal.pone.0073183
176. Perrier S, Jarde T. Adiponectin, an anti-carcinogenic hormone? A systematic
review on breast, colorectal, liver and prostate cancer. Curr Med Chem (2012)
19:5501–12. doi:10.2174/092986712803833137
177. Zhang J, Hochwald SN. Plasma adiponectin: a possible link between fat
metabolism and pancreatic cancer risk. J Natl Cancer Inst (2013) 105:79–80.
doi:10.1093/jnci/djs522
178. Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, et al.
Adiponectin suppresses colorectal carcinogenesis under the high-fat diet con-
dition. Gut (2008) 57:1531–8. doi:10.1136/gut.2008.159293
www.frontiersin.org May 2014 | Volume 5 | Article 65 | 13
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pérez-Hernández et al. Dysregulation of adipose tissue and cancer development
179. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in can-
cer: a review of current evidence. Endocr Rev (2012) 33:547–94. doi:10.1210/
er.2011-1015
180. Clemons N, Phillips W, Lord RV. Signaling pathways in the molecular patho-
genesis of adenocarcinomas of the esophagus and gastresophageal junction.
Cancer Biol Ther (2013) 14:782–95. doi:10.4161/cbt.25362
181. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional
cloning of the mouse obese gene and its human homologue. Nature (1994)
372:425–32. doi:10.1038/372425a0
182. Frühbeck G. Intracellular signalling pathways activated by leptin. Biochem J
(2006) 393:7–20. doi:10.1042/BJ20051578
183. Frühbeck G. Peripheral actions of leptin and its involvement in disease. Nutr
Rev (2002) 60:S47–55. doi:10.1301/002966402320634931
184. Frühbeck G. A heliocentric view of leptin. Proc Nutr Soc (2001) 60:301–18.
doi:10.1079/PNS200196
185. Ryan AS, Berman DM, Nicklas BJ, Sinha M, Gingerich RL, Meneilly GS, et al.
Plasma adiponectin and leptin levels, body composition, and glucose utiliza-
tion in adult women with wide ranges of age and obesity. Diabetes Care (2003)
26:2383–8. doi:10.2337/diacare.26.8.2383
186. Cheng SP, Yin PH, Chang YC, Lee CH, Huang SY, Chi CW. Differential roles
of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep (2010)
23:1721–7. doi:10.3892/or_00000817
187. Zheng Q, Banaszak L, Fracci S, Basali D, Dunlap SM, Hursting SD, et al.
Leptin receptor maintains cancer stem-like properties in triple negative breast
cancer cells. Endocr Relat Cancer (2013) 20:797–808. doi:10.1530/ERC-13-
0329
188. Howard JM, Pidgeon GP, Reynolds JV. Leptin and gastro-intestinal malignan-
cies. Obes Rev (2010) 11:863–74. doi:10.1111/j.1467-789X.2010.00718.x
189. Uddin S, Bu R, Ahmed M, Hussain AR, Ajarim D, Al-Dayel F, et al. Lep-
tin receptor expression and its association with PI3K/AKT signaling path-
way in diffuse large B-cell lymphoma. Leuk Lymphoma (2010) 51:1305–14.
doi:10.3109/10428191003802365
190. Simons PJ, van den Pangaart PS, van Roomen CP, Aerts JM, Boon L. Cytokine-
mediated modulation of leptin and adiponectin secretion during in vitro adi-
pogenesis: evidence that tumor necrosis factor-α- and interleukin-1β-treated
human preadipocytes are potent leptin producers. Cytokine (2005) 32:94–103.
doi:10.1016/j.cyto.2005.08.003
191. Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N. Leptin
signaling in breast cancer: an overview. J Cell Biochem (2008) 105:956–64.
doi:10.1002/jcb.21911
192. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor
necrosis factor-α: direct role in obesity-linked insulin resistance. Science (1993)
259:87–91. doi:10.1126/science.7678183
193. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged
sword. Nat Rev Immunol (2003) 3:745–56. doi:10.1038/nri1184
194. Sethi G, Sung B,Aggarwal BB. TNF: a master switch for inflammation to cancer.
Front Biosci (2008) 13:5094–107. doi:10.2741/3066
195. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 9:361–71.
doi:10.1038/nrc2628
196. Balkwill F. TNF-α in promotion and progression of cancer. Cancer Metastasis
Rev (2006) 25:409–16. doi:10.1007/s10555-006-9005-3
197. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-κB
functions as a tumour promoter in inflammation-associated cancer. Nature
(2004) 431:461–6. doi:10.1038/nature02924
198. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necro-
sis factor and its receptors in human ovarian cancer. Potential role in disease
progression. J Clin Invest (1993) 91:2194–206. doi:10.1172/JCI116446
199. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, et al. The
clinical significance of tumor necrosis factor-α plasma level in patients having
chronic lymphocytic leukemia. Blood (2002) 100:1215–9.
200. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V. Mul-
tifaceted link between cancer and inflammation. Biosci Rep (2012) 32:1–15.
doi:10.1042/BSR20100136
201. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in can-
cer: implications for translational therapeutics. Cancer (2007) 110:1911–28.
doi:10.1002/cncr.22999
202. Naugler WE, Karin M. The wolf in sheep’s clothing: the role of interleukin-6
in immunity, inflammation and cancer. Trends Mol Med (2008) 14:109–19.
doi:10.1016/j.molmed.2007.12.007
203. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflam-
mation, and cancer. J Clin Invest (2007) 117:1175–83. doi:10.1172/JCI31537
204. Angelo LS, Talpaz M, Kurzrock R. Autocrine interleukin-6 production in
renal cell carcinoma: evidence for the involvement of p53. Cancer Res (2002)
62:932–40.
205. Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, et al. Involvement of
proinflammatory cytokines IL-1β and IL-6 in progression of human gastric
carcinoma. Anticancer Res (2005) 25:709–13.
206. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of
colorectal cancer. J Surg Oncol (2003) 83:222–6. doi:10.1002/jso.10269
207. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol
Oncol Clin North Am (1992) 6:273–84.
208. Ghosh S, Ashcraft K. An IL-6 link between obesity and cancer. Front Biosci
(2013) 5:461–78. doi:10.2741/E628
209. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, et al. Signaling
by IL-6 promotes alternative activation of macrophages to limit endotoxemia
and obesity-associated resistance to insulin. Nat Immunol (2014) 15:423–30.
doi:10.1038/ni.2865
210. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-
inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta
(2011) 1813:878–88. doi:10.1016/j.bbamcr.2011.01.034
211. Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various popu-
lations: a systematic review and meta-analysis. Obes Rev (2013) 14:232–44.
doi:10.1111/obr.12003
212. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association
between circulating concentrations of C reactive protein and cancer. J Epi-
demiol Community Health (2007) 61:824–33. doi:10.1136/jech.2006.051292
213. Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein levels and subsequent
cancer outcomes: results from a prospective cohort study. Eur J Cancer (2006)
42:704–7. doi:10.1016/j.ejca.2006.01.008
214. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma
C-reactive protein and risk of cancer: a prospective study from Greece. Cancer
Epidemiol Biomarkers Prev (2006) 15:381–4. doi:10.1158/1055-9965.EPI-05-
0626
215. Baba H, Kuwabara K, Ishiguro T, Hatano S, Matsuzawa T, Fukuchi M, et al.
C-reactive protein as a significant prognostic factor for stage IV gastric cancer
patients. Anticancer Res (2013) 33:5591–5.
216. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al.
The hormone resistin links obesity to diabetes. Nature (2001) 409:307–12.
doi:10.1038/35053000
217. Dupont J, Reverchon M, Cloix L, Froment P, Rame C. Involvement of
adipokines, AMPK, PI3K and the PPAR signaling pathways in ovarian folli-
cle development and cancer. Int J Dev Biol (2012) 56:959–67. doi:10.1387/ijdb.
120134jd
218. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator
of inflammation: implications for various human pathologies. Clin Immunol
(2009) 133:157–70. doi:10.1016/j.clim.2009.07.013
219. Hsu WY, Chao YW, Tsai YL, Lien CC, Chang CF, Deng MC, et al. Resistin
induces monocyte-endothelial cell adhesion by increasing ICAM-1 and
VCAM-1 expression in endothelial cells via p38MAPK-dependent pathway.
J Cell Physiol (2011) 226:2181–8. doi:10.1002/jcp.22555
220. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al.
Adipocytokines as new promising markers of colorectal tumors: adiponectin
for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer
Sci (2010) 101:1286–91. doi:10.1111/j.1349-7006.2010.01518.x
221. Jiang CY, Wang W, Yin YL, Yuan ZR, Wang LB. Expression of the adipocy-
tokine resistin and its association with the clinicopathological features and
prognosis of pancreatic ductal adenocarcinoma. Oncol Lett (2012) 4:960–4.
doi:10.3892/ol.2012.865
222. Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M, Kaplan RC, et al.
Adipokines linking obesity with colorectal cancer risk in postmenopausal
women. Cancer Res (2012) 72:3029–37. doi:10.1158/0008-5472.CAN-11-2771
223. Di Simone N, Di Nicuolo F, Sanguinetti M, Castellani R, D’Asta M, Caforio
L, et al. Resistin regulates human choriocarcinoma cell invasive behaviour
and endothelial cell angiogenic processes. J Endocrinol (2006) 189:691–9.
doi:10.1677/joe.1.06610
224. Catalán V, Gómez-Ambrosi J, Ramírez B, Rotellar F, Pastor C, Silva C, et al.
Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and
gastric bypass. Obes Surg (2007) 17:1464–74. doi:10.1007/s11695-008-9424-z
Frontiers in Endocrinology | Cancer Endocrinology May 2014 | Volume 5 | Article 65 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pérez-Hernández et al. Dysregulation of adipose tissue and cancer development
225. Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol
Lett (2009) 123:97–102. doi:10.1016/j.imlet.2009.02.011
226. Hong S, Zhang P, Zhang H, Jia L, Qu X, Yang Q, et al. Enforced effect of tk-
MCP-1 fusion gene in ovarian cancer. J Exp Clin Cancer Res (2012) 31:74.
doi:10.1186/1756-9966-31-74
227. Matte I, Lane D, Laplante C, Rancourt C, Piche A. Profiling of cytokines in
human epithelial ovarian cancer ascites. Am J Cancer Res (2012) 2:566–80.
228. Baier PK, Eggstein S, Wolff-Vorbeck G, Baumgartner U, Hopt UT. Chemokines
in human colorectal carcinoma. Anticancer Res (2005) 25:3581–4.
229. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K,
et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.
Science (2005) 307:426–30. doi:10.1126/science.1097243
230. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F, et al.
Association of increased visfatin/PBEF/NAMPT circulating concentrations and
gene expression levels in peripheral blood cells with lipid metabolism and fatty
liver in human morbid obesity. Nutr Metab Cardiovasc Dis (2011) 21:245–53.
doi:10.1016/j.numecd.2009.09.008
231. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K,
et al. Retraction. Science (2007) 318:565. doi:10.1126/science.318.5850.565b
232. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, et al.
Nampt/PBEF/visfatin regulates insulin secretion in β cells as a systemic
NAD biosynthetic enzyme. Cell Metab (2007) 6:363–75. doi:10.1016/j.cmet.
2007.09.003
233. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine din-
ucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gas-
troenterol (2007) 23:164–70. doi:10.1097/MOG.0b013e32801b3c8f
234. Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther (2010)
10:119–25. doi:10.4161/cbt.10.2.12581
235. Hufton SE, Moerkerk PT, Brandwijk R, de Bruine AP, Arends JW, Hoogen-
boom HR. A profile of differentially expressed genes in primary colorectal can-
cer using suppression subtractive hybridization. FEBS Lett (1999) 463:77–82.
doi:10.1016/S0014-5793(99)01578-1
236. Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruine AP, Arends JW, Hoogen-
boom HR, et al. Target validation for genomics using peptide-specific phage
antibodies: a study of five gene products overexpressed in colorectal cancer. Int
J Cancer (2002) 101:118–27. doi:10.1002/ijc.10584
237. Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, Netto MM,
et al. Gene expression profile associated with response to doxorubicin-based
therapy in breast cancer. Clin Cancer Res (2005) 11:7434–43. doi:10.1158/1078-
0432.CCR-04-0548
238. Gómez-Ambrosi J, Rodríguez A, Catalán V, Frühbeck G. The bone-adipose axis
in obesity and weight loss. Obes Surg (2008) 18:1134–43. doi:10.1007/s11695-
008-9548-1
239. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB,
et al. Osteopontin mediates obesity-induced adipose tissue macrophage infil-
tration and insulin resistance in mice. J Clin Invest (2007) 117:2877–88.
doi:10.1172/JCI31986
240. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and
cancer progression. Trends Cell Biol (2006) 16:79–87. doi:10.1016/j.tcb.2005.
12.005
241. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-
promoting protein osteopontin in the tumour microenvironment. J Cell Mol
Med (2010) 14:2037–44. doi:10.1111/j.1582-4934.2010.01115.x
242. Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, et al. Osteopontin as potential
biomarker and therapeutic target in gastric and liver cancers. World J Gastroen-
terol (2012) 18:3923–30. doi:10.3748/wjg.v18.i30.3923
243. El-Mesallamy HO, Mostafa AM, Amin AI, El Demerdash E. The interplay of
YKL-40 and leptin in type 2 diabetic obese patients. Diabetes Res Clin Pract
(2011) 93:e113–6. doi:10.1016/j.diabres.2011.05.040
244. Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation
to insulin resistance and with a role in endothelial dysfunction and atheroscle-
rosis. Inflamm Res (2006) 55:221–7. doi:10.1007/s00011-006-0076-y
245. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with
inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull (2006)
53:172–209.
246. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, et al. Inte-
grated array-comparative genomic hybridization and expression array profiles
identify clinically relevant molecular subtypes of glioblastoma. Cancer Res
(2005) 65:1678–86. doi:10.1158/0008-5472.CAN-04-2921
247. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, et al. Gene
expression in papillary thyroid carcinoma reveals highly consistent profiles.
Proc Natl Acad Sci U S A (2001) 98:15044–9. doi:10.1073/pnas.251547398
248. Sjogren H, Meis-Kindblom JM, Orndal C, Bergh P, Ptaszynski K, Aman
P, et al. Studies on the molecular pathogenesis of extraskeletal myxoid
chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analy-
ses. Am J Pathol (2003) 162:781–92. doi:10.1016/S0002-9440(10)63875-8
249. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new
prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev
(2006) 15:194–202. doi:10.1158/1055-9965.EPI-05-0011
250. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol (2011)
194:7–15. doi:10.1083/jcb.201102095
251. Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU. 4-Hydroxynonenal
as a biological signal: molecular basis and pathophysiological implications.
Antioxid Redox Signal (1999) 1:255–84. doi:10.1089/ars.1999.1.3-255
252. Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the
question. Cancer Biol Ther (2008) 7:1875–84. doi:10.4161/cbt.7.12.7067
253. Son Y, Kim S, Chung HT, Pae HO. Reactive oxygen species in the activation
of MAP kinases. Methods Enzymol (2013) 528:27–48. doi:10.1016/B978-0-12-
405881-1.00002-1
254. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al.
Increased oxidative stress in obesity and its impact on metabolic syndrome.
J Clin Invest (2004) 114:1752–61. doi:10.1172/JCI21625
255. Matsuda M, Shimomura I. Increased oxidative stress in obesity: implica-
tions for metabolic syndrome, diabetes, hypertension, dyslipidemia, athero-
sclerosis, and cancer. Obes Res Clin Pract (2013) 7:e330–41. doi:10.1016/j.orcp.
2013.05.004
256. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al.
Obesity and systemic oxidative stress: clinical correlates of oxidative stress
in the Framingham Study. Arterioscler Thromb Vasc Biol (2003) 23:434–9.
doi:10.1161/01.ATV.0000058402.34138.11
257. Okuno Y, Matsuda M, Kobayashi H, Morita K, Suzuki E, Fukuhara A, et al. Adi-
pose expression of catalase is regulated via a novel remote PPARγ-responsive
region. Biochem Biophys Res Commun (2008) 366:698–704. doi:10.1016/j.bbrc.
2007.12.001
258. Kobayashi H, Matsuda M, Fukuhara A, Komuro R, Shimomura I. Dysregu-
lated glutathione metabolism links to impaired insulin action in adipocytes.
Am J Physiol Endocrinol Metab (2009) 296:E1326–34. doi:10.1152/ajpendo.
90921.2008
259. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm
Sci (2007) 96:2181–96. doi:10.1002/jps.20874
260. Pelicano H,Carney D,Huang P. ROS stress in cancer cells and therapeutic impli-
cations. Drug Resist Updat (2004) 7:97–110. doi:10.1016/j.drup.2004.01.004
261. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and
significance. Am J Clin Nutr (1993) 57:715S–24S.
262. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, et al.
Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-
binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol
(2004) 150:161–71. doi:10.1530/eje.0.1500161
263. Warner M, Gustafsson JA. On estrogen, cholesterol metabolism, and breast
cancer. N Engl J Med (2014) 370:572–3. doi:10.1056/NEJMcibr1315176
264. Cleary MP, Grossmann ME. Minireview: obesity and breast cancer: the estrogen
connection. Endocrinology (2009) 150:2537–42. doi:10.1210/en.2009-0070
265. Leslie KK, Thiel KW, Reyes HD, Yang S, Zhang Y, Carlson MJ, et al. The estro-
gen receptor joins other cancer biomarkers as a predictor of outcome. Obstet
Gynecol Int (2013) 2013:479541. doi:10.1155/2013/479541
266. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, et al. Genome-
wide analysis of estrogen receptor binding sites. Nat Genet (2006) 38:1289–97.
doi:10.1038/ng1901
267. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis
S, et al. Effects of estrogen on global gene expression: identification of novel
targets of estrogen action. Cancer Res (2000) 60:5977–83.
268. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Pro-
filing of estrogen up- and down-regulated gene expression in human breast
cancer cells: insights into gene networks and pathways underlying estrogenic
control of proliferation and cell phenotype. Endocrinology (2003) 144:4562–74.
doi:10.1210/en.2003-0567
269. Stocco C. Tissue physiology and pathology of aromatase. Steroids (2012)
77:27–35. doi:10.1016/j.steroids.2011.10.013
www.frontiersin.org May 2014 | Volume 5 | Article 65 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pérez-Hernández et al. Dysregulation of adipose tissue and cancer development
270. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast
cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl
Cancer Inst (2002) 94:606–16.
271. Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal
breast cancer: a quantitative review. Cancer Causes Control (1997) 8:922–8.
doi:10.1023/A:1018476631561
272. Carlson MJ, Thiel KW, Yang S, Leslie KK. Catch it before it kills: proges-
terone, obesity, and the prevention of endometrial cancer. Discov Med (2012)
14:215–22.
273. Kahn CR, White MF. The insulin receptor and the molecular mechanism of
insulin action. J Clin Invest (1988) 82:1151–6. doi:10.1172/JCI113711
274. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic con-
trol and insulin signaling. Circ Res (2007) 100:328–41. doi:10.1161/01.RES.
0000256090.42690.05
275. Xu XJ, Pories WJ, Dohm LG, Ruderman NB. What distinguishes adipose tissue
of severely obese humans who are insulin sensitive and resistant? Curr Opin
Lipidol (2013) 24:49–56. doi:10.1097/MOL.0b013e32835b465b
276. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnos-
tic body-mass index, plasma C-peptide concentration, and prostate cancer-
specific mortality in men with prostate cancer: a long-term survival analysis.
Lancet Oncol (2008) 9:1039–47. doi:10.1016/S1470-2045(08)70235-3
277. Liu Z, Yan R, Al-Salman A, Shen Y, Bu Y, Ma J, et al. Epidermal growth fac-
tor induces tumour marker AKR1B10 expression through activator protein-
1 signalling in hepatocellular carcinoma cells. Biochem J (2012) 442:273–82.
doi:10.1042/BJ20111322
278. Wang Y, Hua S, Tian W, Zhang L, Zhao J, Zhang H, et al. Mitogenic and anti-
apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-
kinase/Akt dependent. Gynecol Oncol (2012) 125:734–41. doi:10.1016/j.ygyno.
2012.03.012
279. Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi
Y, et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat
Cancer (2013) 20:R1–17. doi:10.1530/ERC-12-0324
280. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role
of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev (2009)
18:2569–78. doi:10.1158/1055-9965.EPI-09-0372
281. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins:
biological actions. Endocr Rev (1995) 16:3–34. doi:10.1210/edrv-16-1-3
282. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al.
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective
study. Science (1998) 279:563–6. doi:10.1126/science.279.5350.563
283. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al.
Circulating concentrations of insulin-like growth factor-I and risk of breast
cancer. Lancet (1998) 351:1393–6. doi:10.1016/S0140-6736(97)10384-1
284. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al.
Prospective study of colorectal cancer risk in men and plasma levels of insulin-
like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst (1999)
91:620–5. doi:10.1093/jnci/91.23.2052
285. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like
growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst
(1999) 91:151–6. doi:10.1093/jnci/91.2.151
286. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer devel-
opment and progression. J Natl Cancer Inst (2000) 92:1472–89. doi:10.1093/
jnci/92.18.1472
287. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review
of the evidence. J Nutr (2001) 131:3109S–20S.
288. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M.
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk:
systematic review and meta-regression analysis. Lancet (2004) 363:1346–53.
doi:10.1016/S0140-6736(04)16044-3
289. Trayhurn P. Hypoxia and adipose tissue function and dysfunction in obesity.
Physiol Rev (2013) 93:1–21. doi:10.1152/physrev.00017.2012
290. Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on
mechanisms linking obesity to cancer risk and progression. Annu Rev Med
(2013) 64:45–57. doi:10.1146/annurev-med-121211-091527
291. Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, et al. High-
mobility group box 1 activates caspase-1 and promotes hepatocellular car-
cinoma invasiveness and metastases. Hepatology (2012) 55:1863–75. doi:10.
1002/hep.25572
292. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in
the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 8:618–31.
doi:10.1038/nrc2444
293. Weigert A, Brune B. Nitric oxide, apoptosis and macrophage polarization dur-
ing tumor progression. Nitric Oxide (2008) 19:95–102. doi:10.1016/j.niox.
2008.04.021
294. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V,
et al. NF-κB links innate immunity to the hypoxic response through tran-
scriptional regulation of HIF-1α. Nature (2008) 453:807–11. doi:10.1038/
nature06905
295. Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment
of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood
(2004) 104:2224–34. doi:10.1182/blood-2004-03-1109
296. Yamada S, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Arakawa Y, et al.
Expressions of hypoxia-inducible factor-1 and epithelial cell adhesion mole-
cule are linked with aggressive local recurrence of hepatocellular carcinoma
after radiofrequency ablation therapy. Ann Surg Oncol (2014). doi:10.1245/
s10434-014-3575-z
297. Tsai YP, Wu KJ. Hypoxia-regulated target genes implicated in tumor metastasis.
J Biomed Sci (2012) 19:102. doi:10.1186/1423-0127-19-102
298. Semenza GL. Molecular mechanisms mediating metastasis of hypoxic breast
cancer cells. Trends Mol Med (2012) 18:534–43. doi:10.1016/j.molmed.2012.
08.001
299. Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL, et al. Emerg-
ing metabolic targets in cancer therapy. Front Biosci (2011) 16:1844–60.
doi:10.2741/3826
300. Kizaka-Kondoh S, Kuchimaru T, Kadonosono T. Pathophysiological response
to hypoxia – from the molecular mechanisms of malady to drug discovery:
hypoxia-inducible factor-1 (HIF-1)-active cells as a target for cancer therapy.
J Pharmacol Sci (2011) 115:440–5. doi:10.1254/jphs.10R20FM
301. Nagasawa H. Pathophysiological response to hypoxia – from the molecular
mechanisms of malady to drug discovery: drug discovery for targeting the
tumor microenvironment. J Pharmacol Sci (2011) 115:446–52. doi:10.1254/
jphs.10R25FM
302. Thomson CA, McCullough ML, Wertheim BC, Chlebowski RT, Martinez ME,
Stefanick ML, et al. Nutrition and physical activity cancer prevention guide-
lines, cancer risk, and mortality in the women’s health initiative. Cancer Prev
Res (2014) 7:42–53. doi:10.1158/1940-6207.CAPR-13-0258
303. Caponi PW, Lehnen AM, Pinto GH, Borges J, Markoski M, Machado UF,
et al. Aerobic exercise training induces metabolic benefits in rats with meta-
bolic syndrome independent of dietary changes. Clinics (2013) 68:1010–7.
doi:10.6061/clinics/2013(07)20
304. Jakicic JM, Otto AD, Lang W, Semler L, Winters C, Polzien K, et al. The effect
of physical activity on 18-month weight change in overweight adults. Obesity
(2011) 19:100–9. doi:10.1038/oby.2010.122
305. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney
JS, et al. Effects of the amount and intensity of exercise on plasma lipoproteins.
N Engl J Med (2002) 347:1483–92. doi:10.1056/NEJMoa020194
306. Halle M, Berg A, Konig D, Keul J, Baumstark MW. Differences in the con-
centration and composition of low-density lipoprotein subfraction particles
between sedentary and trained hypercholesterolemic men. Metabolism (1997)
46:186–91. doi:10.1016/S0026-0495(97)90300-0
307. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker
EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle inter-
vention or metformin. N Engl J Med (2002) 346:393–403. doi:10.1056/
NEJMoa012512
308. Gibney J, Healy ML, Sonksen PH. The growth hormone/insulin-like growth
factor-I axis in exercise and sport. Endocr Rev (2007) 28:603–24. doi:10.1210/
er.2006-0052
309. Katzmarzyk PT, Janssen I, Ardern CI. Physical inactivity, excess adiposity and
premature mortality. Obes Rev (2003) 4:257–90. doi:10.1046/j.1467-789X.
2003.00120.x
310. Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as
compared with physical activity in predicting mortality among women. N Engl
J Med (2004) 351:2694–703. doi:10.1056/NEJMoa042135
311. Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK. Physical
exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst
(1994) 86:1403–8. doi:10.1093/jnci/86.18.1403
Frontiers in Endocrinology | Cancer Endocrinology May 2014 | Volume 5 | Article 65 | 16
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pérez-Hernández et al. Dysregulation of adipose tissue and cancer development
312. Chlebowski RT. Nutrition and physical activity influence on breast cancer inci-
dence and outcome. Breast (2013) 22(Suppl 2):S30–7. doi:10.1016/j.breast.
2013.07.006
313. Boyle T, Fritschi L, Platell C, Heyworth J. Lifestyle factors associated with
survival after colorectal cancer diagnosis. Br J Cancer (2013) 109:814–22.
doi:10.1038/bjc.2013.310
314. Song JH, Kim YS, Yang SY, Chung SJ, Park MJ, Lim SH, et al. Physical activity
and other lifestyle factors in relation to the prevalence of colorectal adenoma:
a colonoscopy-based study in asymptomatic Koreans. Cancer Causes Control
(2013) 24:1717–26. doi:10.1007/s10552-013-0247-4
315. Rebillard A, Lefeuvre-Orfila L, Gueritat J, Cillard J. Prostate cancer and phys-
ical activity: adaptive response to oxidative stress. Free Radic Biol Med (2013)
60:115–24. doi:10.1016/j.freeradbiomed.2013.02.009
316. McMillan DC, Sattar N, McArdle CS. ABC of obesity. Obesity and cancer. BMJ
(2006) 333:1109–11. doi:10.1136/bmj.39042.565035.BE1
317. Jing K, Wu T, Lim K. ω-3 polyunsaturated fatty acids and cancer. Anticancer
Agents Med Chem (2013) 13:1162–77. doi:10.2174/18715206113139990319
318. Laviano A, Rianda S, Molfino A, Rossi Fanelli F. ω-3 fatty acids in can-
cer. Curr Opin Clin Nutr Metab Care (2013) 16:156–61. doi:10.1097/MCO.
0b013e32835d2d99
319. Cockbain AJ, Volpato M, Race AD, Munarini A, Fazio C, Belluzzi A, et al.
Anticolorectal cancer activity of the ω-3 polyunsaturated fatty acid eicosapen-
taenoic acid. Gut (2014). doi:10.1136/gutjnl-2013-306445
320. Gu Z, Suburu J, Chen H, Chen YQ. Mechanisms of ω-3 polyunsaturated
fatty acids in prostate cancer prevention. Biomed Res Int (2013) 2013:824563.
doi:10.1155/2013/824563
321. Chen Z, Odstrcil EA, Tu BP, McKnight SL. Restriction of DNA replication to
the reductive phase of the metabolic cycle protects genome integrity. Science
(2007) 316:1916–9. doi:10.1126/science.1140958
322. Silverman SJ, Petti AA, Slavov N, Parsons L, Briehof R, Thiberge SY, et al. Meta-
bolic cycling in single yeast cells from unsynchronized steady-state populations
limited on glucose or phosphate. Proc Natl Acad Sci U S A (2010) 107:6946–51.
doi:10.1073/pnas.1002422107
323. Dang CV. Links between metabolism and cancer. Genes Dev (2012) 26:877–90.
doi:10.1101/gad.189365.112
324. Friberg E, Wallin A, Wolk A. Sucrose, high-sugar foods, and risk of endometrial
cancer – a population-based cohort study. Cancer Epidemiol Biomarkers Prev
(2011) 20:1831–7. doi:10.1158/1055-9965.EPI-11-0402
325. Cust AE, Slimani N, Kaaks R, van Bakel M, Biessy C, Ferrari P, et al. Dietary car-
bohydrates, glycemic index, glycemic load, and endometrial cancer risk within
the European prospective investigation into cancer and nutrition cohort.
Am J Epidemiol (2007) 166:912–23. doi:10.1093/aje/kwm161
326. Tasevska N, Jiao L, Cross AJ, Kipnis V, Subar AF, Hollenbeck A, et al. Sugars in
diet and risk of cancer in the NIH-AARP diet and health study. Int J Cancer
(2012) 130:159–69. doi:10.1002/ijc.25990
327. Longo VD, Fontana L. Calorie restriction and cancer prevention: meta-
bolic and molecular mechanisms. Trends Pharmacol Sci (2010) 31:89–98.
doi:10.1016/j.tips.2009.11.004
328. Brethauer SA, Aminian A, Romero-Talamas H, Batayyah E, Mackey J, Kennedy
L, et al. Can diabetes be surgically cured? Long-term metabolic effects of
bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg
(2013) 258:628–37. doi:10.1097/SLA.0b013e3182a5034b
329. Guo X, Liu X, Wang M, Wei F, Zhang Y. The effects of bariatric procedures
versus medical therapy for obese patients with type 2 diabetes: meta-analysis
of randomized controlled trials. Biomed Res Int (2013) 2013:410609. doi:10.
1155/2013/410609
330. Nestvold TK, Nielsen EW, Lappegard KT. Bariatric surgery reduces risk factors
for development of type 2 diabetes mellitus in morbidly obese, nondiabetic
patients. Metab Syndr Relat Disord (2013) 11:441–6. doi:10.1089/met.2013.
0085
331. Greenburg DL, Lettieri CJ, Eliasson AH. Effects of surgical weight loss on mea-
sures of obstructive sleep apnea: a meta-analysis. Am J Med (2009) 122:535–42.
doi:10.1016/j.amjmed.2008.10.037
332. Laimer MW, Engl J, Tschoner A, Kaser S, Ritsch A, Tatarczyk T, et al. Effects of
weight loss on lipid transfer proteins in morbidly obese women. Lipids (2009)
44:1125–30. doi:10.1007/s11745-009-3349-8
333. Moretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC. Effect of bariatric
surgery on liver fibrosis. Obes Surg (2012) 22:1044–9. doi:10.1007/s11695-011-
0559-y
334. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Cardiovascular bene-
fits of bariatric surgery in morbidly obese patients. Obes Rev (2011) 12:515–24.
doi:10.1111/j.1467-789X.2010.00831.x
335. Ikramuddin S, Livingston EH. New insights on bariatric surgery outcomes.
JAMA (2013) 310:2401–2. doi:10.1001/jama.2013.280927
336. Christou NV, Lieberman M, Sampalis F, Sampalis JS. Bariatric surgery reduces
cancer risk in morbidly obese patients. Surg Obes Relat Dis (2008) 4:691–5.
doi:10.1016/j.soard.2008.08.025
337. Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC, et al.
Cancer incidence and mortality after gastric bypass surgery. Obesity (2009)
17:796–802. doi:10.1038/oby.2008.610
338. Ashrafian H, Ahmed K, Rowland SP, Patel VM, Gooderham NJ, Holmes E, et al.
Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer
(2011) 117:1788–99. doi:10.1002/cncr.25738
339. Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H,
et al. Effects of bariatric surgery on cancer incidence in obese patients in Swe-
den (Swedish Obese Subjects Study): a prospective, controlled intervention
trial. Lancet Oncol (2009) 10:653–62. doi:10.1016/S1470-2045(09)70159-7
340. Renehan AG. Bariatric surgery, weight reduction, and cancer prevention. Lancet
Oncol (2009) 10:640–1. doi:10.1016/S1470-2045(09)70170-6
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 04 March 2014; paper pending published: 22 March 2014; accepted: 15 April
2014; published online: 01 May 2014.
Citation: Pérez-Hernández AI, Catalán V, Gómez-Ambrosi J, Rodríguez A and Früh-
beck G (2014) Mechanisms linking excess adiposity and carcinogenesis promotion.
Front. Endocrinol. 5:65. doi: 10.3389/fendo.2014.00065
This article was submitted to Cancer Endocrinology, a section of the journal Frontiers
in Endocrinology.
Copyright © 2014 Pérez-Hernández, Catalán, Gómez-Ambrosi, Rodríguez and Früh-
beck. This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
www.frontiersin.org May 2014 | Volume 5 | Article 65 | 17
